

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>Recent advances in the management of non-small cell... | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/6-2110/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/6-2110" />
    
            <meta name="description" content="Read the original article in full on F1000Research: Recent advances in the management of non-small cell lung cancer" />
    
            <meta name="og:title" content="F1000Research Article: Recent advances in the management of non-small cell lung cancer.">
            <meta name="og:description" content="Read the latest article version by Samira Shojaee, Patrick Nana-Sinkam, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="12385">
            <meta name="article-id" content="11471">
            <meta name="dc.title" content="Recent advances in the management of non-small cell lung cancer">
            <meta name="dc.description" content="Lung cancer is the number one cause of cancer-related death in both men and women. However, over the last few years, we have witnessed improved outcomes that are largely attributable to early detection, increased efforts in tobacco control, improved surgical approaches, and the development of novel targeted therapies. Currently, there are several novel therapies in clinical practice, including those targeting actionable mutations and more recently immunotherapeutic agents. Immunotherapy represents the most significant step forward in eradicating this deadly disease. Given the ever-changing landscape of lung cancer management, here we present an overview of the most recent advances in the management of non-small cell lung cancer.">
            <meta name="dc.subject" content="EGFR, Non-Small Cell Lung Cancer, ALK mutation">
            <meta name="dc.creator" content="Shojaee, Samira">
            <meta name="dc.creator" content="Nana-Sinkam, Patrick">
            <meta name="dc.date" content="2017/12/07">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.11471.1">
            <meta name="dc.source" content="F1000Research 2017 6:2110">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="EGFR">
            <meta name="prism.keyword" content="Non-Small Cell Lung Cancer">
            <meta name="prism.keyword" content="ALK mutation">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2017/12/07">
            <meta name="prism.volume" content="6">
            <meta name="prism.number" content="2110">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.11471.1">
            <meta name="prism.url" content="https://f1000research.com/articles/6-2110">
            <meta name="citation_title" content="Recent advances in the management of non-small cell lung cancer">
            <meta name="citation_abstract" content="Lung cancer is the number one cause of cancer-related death in both men and women. However, over the last few years, we have witnessed improved outcomes that are largely attributable to early detection, increased efforts in tobacco control, improved surgical approaches, and the development of novel targeted therapies. Currently, there are several novel therapies in clinical practice, including those targeting actionable mutations and more recently immunotherapeutic agents. Immunotherapy represents the most significant step forward in eradicating this deadly disease. Given the ever-changing landscape of lung cancer management, here we present an overview of the most recent advances in the management of non-small cell lung cancer.">
            <meta name="citation_description" content="Lung cancer is the number one cause of cancer-related death in both men and women. However, over the last few years, we have witnessed improved outcomes that are largely attributable to early detection, increased efforts in tobacco control, improved surgical approaches, and the development of novel targeted therapies. Currently, there are several novel therapies in clinical practice, including those targeting actionable mutations and more recently immunotherapeutic agents. Immunotherapy represents the most significant step forward in eradicating this deadly disease. Given the ever-changing landscape of lung cancer management, here we present an overview of the most recent advances in the management of non-small cell lung cancer.">
            <meta name="citation_keywords" content="EGFR, Non-Small Cell Lung Cancer, ALK mutation">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Samira Shojaee">
            <meta name="citation_author_institution" content="Division of Pulmonary and Critical Care Medicine, Virginia Commonwealth University, Richmond, USA">
            <meta name="citation_author" content="Patrick Nana-Sinkam">
            <meta name="citation_author_institution" content="Division of Pulmonary and Critical Care Medicine, Virginia Commonwealth University, Richmond, USA">
            <meta name="citation_publication_date" content="2017/12/07">
            <meta name="citation_volume" content="6">
            <meta name="citation_publication_number" content="2110">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.11471.1">
            <meta name="citation_firstpage" content="2110">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/6-2110/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/6-2110.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=12385 /> <input type=hidden id=articleId name=articleId value=11471 /> <input type=hidden id=xmlUrl value="/articles/6-2110/v1/xml"/> <input type=hidden id=xmlFileName value="-6-2110-v1.xml"> <input type=hidden id=article_uuid value=8e23a256-da3b-465b-8d24-de97c29308d5 /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="Recent advances in the management of non-small cell lung cancer"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.11471.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.11471.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/6-2110"
  },
  "headline": "Recent advances in the management of non-small cell lung cancer",
  "datePublished": "2017-12-07T16:35:33",
  "dateModified": "2017-12-07T16:35:33",
  "author": [
    {
      "@type": "Person",
      "name": "Samira Shojaee"
    },    {
      "@type": "Person",
      "name": "Patrick Nana-Sinkam"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "Lung cancer is the number one cause of cancer-related death in both men and women. However, over the last few years, we have witnessed improved outcomes that are largely attributable to early detection, increased efforts in tobacco control, improved surgical approaches, and the development of novel targeted therapies. Currently, there are several novel therapies in clinical practice, including those targeting actionable mutations and more recently immunotherapeutic agents. Immunotherapy represents the most significant step forward in eradicating this deadly disease. Given the ever-changing landscape of lung cancer management, here we present an overview of the most recent advances in the management of non-small cell lung cancer."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/6-2110.html",
            "name": "Recent advances in the management of non-small cell lung cancer"
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> Recent advances in the management of non-small cell lung cancer </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=12385 data-id=11471 data-downloads="" data-views="" data-scholar="10.12688/f1000research.11471.1" data-recommended="" data-doi="10.12688/f1000research.11471.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/6-2110/v1/pdf?article_uuid=8e23a256-da3b-465b-8d24-de97c29308d5" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-11471-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-11471-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-11471-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Shojaee S and Nana-Sinkam P. Recent advances in the management of non-small cell lung cancer [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2017, <b>6</b>(F1000 Faculty Rev):2110 (<a class=new-orange href="https://doi.org/10.12688/f1000research.11471.1" target=_blank>https://doi.org/10.12688/f1000research.11471.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-11471-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=11471 id=track-article-signin-11471 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/11471?target=/articles/6-2110.html">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=12385 /> <input name=articleId type=hidden value=11471 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>Recent advances in the management of non-small cell lung cancer</h1><span class=other-info> [version 1; peer review: 2 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class="">Samira Shojaee<a href="https://orcid.org/0000-0001-9228-209X" target=_blank id=author-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0001-9228-209X</div>,&nbsp;</span><span class=""><a href="mailto:patrick.Nana-Sinkam@vcuhealth.org" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Patrick Nana-Sinkam</span></a></span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class="">Samira Shojaee<a href="http://orcid.org/0000-0001-9228-209X" target=_blank id=mauthor-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0001-9228-209X</div>,&nbsp;</span><span class=""><a href="mailto:patrick.Nana-Sinkam@vcuhealth.org" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Patrick Nana-Sinkam</span></a></span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 07 Dec 2017 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.11471.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> Division of Pulmonary and Critical Care Medicine, Virginia Commonwealth University, Richmond, USA<br/> <p> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=28504-28461></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=28505-28462></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> Lung cancer is the number one cause of cancer-related death in both men and women. However, over the last few years, we have witnessed improved outcomes that are largely attributable to early detection, increased efforts in tobacco control, improved surgical approaches, and the development of novel targeted therapies. Currently, there are several novel therapies in clinical practice, including those targeting actionable mutations and more recently immunotherapeutic agents. Immunotherapy represents the most significant step forward in eradicating this deadly disease. Given the ever-changing landscape of lung cancer management, here we present an overview of the most recent advances in the management of non-small cell lung cancer. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> EGFR, Non-Small Cell Lung Cancer, ALK mutation </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> Patrick Nana-Sinkam (<a href="mailto:patrick.Nana-Sinkam@vcuhealth.org">patrick.Nana-Sinkam@vcuhealth.org</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding author:</b> Patrick Nana-Sinkam </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> No competing interests were disclosed. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> This work was supported by National Cancer Institute grant 1U01CA213330-01 (S.N-S). <br/> <i>The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</i> </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp; © 2017 Shojaee S and Nana-Sinkam P. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Shojaee S and Nana-Sinkam P. Recent advances in the management of non-small cell lung cancer [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2017, <b>6</b>(F1000 Faculty Rev):2110 (<a href="https://doi.org/10.12688/f1000research.11471.1" target=_blank>https://doi.org/10.12688/f1000research.11471.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 07 Dec 2017, <b>6</b>(F1000 Faculty Rev):2110 (<a href="https://doi.org/10.12688/f1000research.11471.1" target=_blank>https://doi.org/10.12688/f1000research.11471.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 07 Dec 2017, <b>6</b>(F1000 Faculty Rev):2110 (<a href="https://doi.org/10.12688/f1000research.11471.1" target=_blank>https://doi.org/10.12688/f1000research.11471.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d2822e159>Personalized targeted therapy</h2><p class="" id=d2822e162>Over the past decade, the treatment of non-small cell lung cancer (NSCLC) has evolved. While early diagnosis and surgical treatment results in optimal patient outcomes, the majority of patients are diagnosed with lung cancer at later, largely incurable stages often requiring multimodality therapy. Over the last decade, we have observed significant improvements in the management of advanced stages primarily due to an increased understanding of the molecular heterogeneity and drivers of lung cancer initiation and progression as well as improvements in radio and surgical therapies. Using high-throughput platforms, investigators have determined that a significant percentage of lung tumors have actionable somatic mutations, each of which represents an opportunity for novel targeted or “personalized” therapy. Investigators have discovered mutations within the epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), fibroblast growth factor receptor (FGFR), ROS-1, KRAS, HER2, BRAF, MET, and RET<sup><a href="#ref-1">1</a>–<a href="#ref-7">7</a></sup>. Through clinical trials, distinct roles for targeted therapies are emerging as standard first- or second-line therapies in patients harboring select mutations.</p><div class=section><a name=d2822e172 class=n-a></a><h3 class=section-title>EGFR mutation</h3><p class="" id=d2822e177>Mutations in EGFR, first discovered in 2004<sup><a href="#ref-8">8</a></sup>, are present in up to 10–15% of all patients with NSCLC<sup><a href="#ref-9">9</a></sup>. Initial studies described the most common demographics as never-smokers, female gender, and Asian ethnicity<sup><a href="#ref-9">9</a>–<a href="#ref-12">12</a></sup>. Mutations are predominantly located in EGFR exons 18–21. A total of 85% of the mutations are either deletions in exon 19 or a single-point substitution mutation in exon 21 (l858R)<sup><a href="#ref-11">11</a>,<a href="#ref-12">12</a></sup>. EGFR tyrosine kinase inhibitors (gefitinib, erlotinib, and afatinib) are the currently available first-line agents for patients harboring EGFR-positive mutations with an estimated initial response rate of 70–80%<sup><a href="#ref-13">13</a>,<a href="#ref-14">14</a></sup>. Patients with stage IV NSCLC and EGFR mutations treated with tyrosine kinase inhibitors experienced improved progression-free survival (PFS), increased response rate, better overall quality of life, and fewer side effects in comparison to those receiving standard platinum-based chemotherapy<sup><a href="#ref-15">15</a></sup>. The majority of patients, however, experience disease progression secondary to acquired resistance. Up to 60% of acquired resistance mutations are driven by T790M<sup><a href="#ref-16">16</a></sup>. T790M is an activating point mutation in exon 20 which substitutes methionine for threonine and interferes with the binding of tyrosine kinase inhibitors<sup><a href="#ref-6">6</a></sup>. Next-generation EGFR tyrosine kinase inhibitors targeting T790M mutations have been developed in the event of resistance to first-line therapy<sup><a href="#ref-17">17</a></sup>. Jänne and colleagues showed that among those with positive T790M mutations and evidence of disease progression on EGFR tyrosine kinase inhibitors, the use of next-generation tyrosine kinase inhibitors with specific T790M targeting such as osimertinib resulted in a response rate of 61% (95% CI: 52–70) as opposed to a response rate of 21% (95% CI: 12–34) when there was no centrally detectable T790M mutation. The authors reported a median PFS of 9.6 months versus 2.8 months in EGFR-T790M-negative patients<sup><a href="#ref-18">18</a>–<a href="#ref-20">20</a></sup>. Osimertinib was approved by the U.S. Food and Drug Administration (FDA) for the treatment of EGFR-T790M-positive NSCLC with disease progression on a prior EGFR tyrosine kinase inhibitor<sup><a href="#ref-20">20</a></sup>. The median overall survival (OS) is likely to improve following the approval of third-generation tyrosine kinase inhibitors such as osimertinib, which showed a median PFS of 9.6 months for patients without central nervous system (CNS) metastasis<sup><a href="#ref-21">21</a>,<a href="#ref-22">22</a></sup>. Additionally, necitumumab, a recently approved second-generation EGFR monoclonal antibody, showed improved OS in advanced squamous NSCLC when combined with cytotoxic chemotherapy<sup><a href="#ref-20">20</a></sup>. In an open-labeled randomized phase III trial in 1,093 patients with stage IV NSCLC, Thatcher <i>et al.</i> showed that OS was significantly prolonged in the necitumumab plus gemcitabine and cisplatin group (OS: 11.5 months [95% CI: 10.4–12.6]) versus gemcitabine and cisplatin alone (OS: 9.9 months [95% CI: 8.9–11.1])<sup><a href="#ref-23">23</a></sup>.</p></div><div class=section><a name=d2822e257 class=n-a></a><h3 class=section-title>ALK rearrangement</h3><p class="" id=d2822e262>A total of 4–5% of NSCLC adenocarcinomas harbor ALK genetic rearrangements. A short inversion in chromosome 2p results in rearrangement of the receptor tyrosine kinase ALK and fusion of the intracellular kinase domain with the amino acid end of echinoderm microtubule-associated protein like 4 (EML4). Many variants of EML4–ALK fusions have been identified, but most commonly exons 1–13 of EML4 join exons 20–29 of ALK<sup><a href="#ref-7">7</a></sup>. EML4–ALK fusion leads to a ligand-independent, constitutive activation of the rearranged ALK receptor, which is responsible for both tumor cell proliferation and survival<sup><a href="#ref-7">7</a>,<a href="#ref-24">24</a></sup>. Frequently detected in young never-smoker males<sup><a href="#ref-25">25</a></sup>, ALK fusions are thought to occur mutually exclusively of EGFR mutations. ALK fusions are primarily sensitive to the ALK inhibitor crizotinib<sup><a href="#ref-7">7</a>,<a href="#ref-24">24</a>,<a href="#ref-25">25</a></sup>. In 2011, the results of 119 ALK-rearranged NSCLC patients were combined with those of 136 ALK-rearranged patients from another trial and formed the efficacy data that led to conditional FDA approval of crizotinib<sup><a href="#ref-26">26</a></sup>. A total of 72% of 119 patients were never-smokers and 97% had adenocarcinoma histology. The response rate was 61% with an estimated PFS of 10 months (95% CI: 8.2–14.7). By 2013, a randomized phase III trial (PROFILE-1007) confirmed the efficacy of crizotinib in ALK-rearranged NSCLC<sup><a href="#ref-27">27</a>–<a href="#ref-29">29</a></sup>. The majority of patients, however, developed resistance relapsing within 12 months<sup><a href="#ref-30">30</a></sup>. Ceritinib, a novel ALK inhibitor, showed greater potency compared to crizotinib in a phase I study of 130 patients. Antitumor activity was independent of prior ALK-inhibitor therapy<sup><a href="#ref-31">31</a>,<a href="#ref-32">32</a></sup>. There was an overall response rate of 58% (95% CI: 48–67). The response rate was also reported at 56% (95% CI: 45–67) among those who had previously received crizotinib. Among patients with NSCLC who received at least 400 mg of ceritinib per day, the median PFS was 7.0 months (95% CI: 5.6–9.5). On April 2014, ceritinib received an accelerated FDA approval for use in patients with metastatic ALK-positive NSCLC who were previously treated with crizotinib. Along with ceritinib, alectinib, another FDA-approved ALK inhibitor, has potential advantages over crizotinib including greater specificity, sensitivity, and ability to cross the blood–brain barrier as well as a different spectrum of activity against resistance mutations<sup><a href="#ref-26">26</a>,<a href="#ref-33">33</a>–<a href="#ref-35">35</a></sup>. While most patients with ALK- or ROS1-positive NSCLC develop resistance to tyrosine kinase inhibitor therapy, loratinib, a selective brain-penetrant ALK/ROS1 tyrosine kinase inhibitor, is active against most known resistance mutations and has been granted FDA breakthrough therapy status. In a study of 54 patients with ALK- or ROS1-positive NSCLC with or without brain metastases, loratinib treatment resulted in durable clinical responses with a 50% overall response rate, including intracranial responses, in ALK- and ROS1-positive NSCLC patients, many of whom had CNS metastases. Nearly 50% of the patients had prior tyrosine kinase inhibitor therapy and 39 patients had CNS metastasis<sup><a href="#ref-35">35</a>,<a href="#ref-36">36</a></sup>.</p></div><div class=section><a name=d2822e331 class=n-a></a><h3 class=section-title>KRAS and MEK mutation</h3><p class="" id=d2822e336>Kirsten rat sarcoma viral oncogene (<i>KRAS</i>), a RAS proto-oncogene, has a critical role in signal transduction pathways that regulate cell proliferation, differentiation, and survival. Among the activated downstream pathways from RAS is the mitogen-activated protein kinase (MAPK). MEK1 (also known as MAP2K1), a serine-threonine kinase, affects the regulation of growth-regulating proteins. KRAS mutations are the most common driver alterations, found in up to 25% of all patients with adenocarcinoma<sup><a href="#ref-1">1</a></sup>. Targeting KRAS itself has been challenging, primarily because KRAS activates multiple downstream effectors, including MEK, among many others. MEK1 inhibitors in the setting of RAS mutations are currently undergoing testing<sup><a href="#ref-37">37</a>–<a href="#ref-39">39</a></sup>. Tao <i>et al.</i> recently demonstrated that KRAS mutations can drive increased expression of cyclin-dependent kinase 4 (CDK4) and cyclin D1, facilitating cell proliferation and thus tumorigenesis<sup><a href="#ref-40">40</a></sup>. Additionally, a synthetic interaction between KRAS and CDK4 in animal models has proven to be lethal<sup><a href="#ref-41">41</a></sup>. While there is no specific targeted therapy for KRAS mutations, pre-clinical data suggest that the MEK inhibitor trametinib in combination with a CDK4/6 inhibitor (palbociclib) has significant anti-KRAS-mutant NSCLC activity<sup><a href="#ref-40">40</a></sup>.</p></div><div class=section><a name=d2822e371 class=n-a></a><h3 class=section-title>ROS1 mutation</h3><p class="" id=d2822e376>The <i>ROS1</i> proto-oncogene receptor tyrosine kinase (ROS1) is activated by chromosomal rearrangement, which leads to the fusion of a portion of ROS1 that includes the entire tyrosine kinase domain with 1 of 12 different partner proteins<sup><a href="#ref-42">42</a></sup> The ROS1 fusion kinases are then activated and result in cellular transformation. A total of 1% of patients with NSCLC have ROS1 rearrangements, and they are commonly found in never-smokers with histologic features of adenocarcinoma<sup><a href="#ref-43">43</a></sup>. The kinase domains of ALK and ROS1 share 77% amino acid identity within the ATP-binding sites. Crizotinib binds with high affinity to both ALK and ROS1<sup><a href="#ref-42">42</a>,<a href="#ref-44">44</a>,<a href="#ref-45">45</a></sup>. Shaw and colleagues noted that crizotinib showed marked antitumor activity in patients with advanced ROS1-rearranged NSCLC<sup><a href="#ref-46">46</a></sup>. In March 2016, the FDA approved crizotinib for the treatment of patients with metastatic NSCLC whose tumors are ROS1 positive.</p></div><div class=section><a name=d2822e405 class=n-a></a><h3 class=section-title>MET mutation</h3><p class="" id=d2822e410>The <i>MET</i> receptor tyrosine kinase is a known oncogene, with a somatic mutation frequency of 8.3% in lung adenocarcinoma and 2% in lung squamous cell carcinoma<sup><a href="#ref-47">47</a></sup>. Unlike activating <i>EGFR</i> mutations that occur primarily in the tyrosine kinase domain, <i>MET</i> mutations are distributed across all domains of the gene<sup><a href="#ref-48">48</a></sup>. MET can be activated as a primary oncogenic driver in NSCLC in at least two main ways: high-level <i>MET</i> amplification and <i>MET</i> exon 14 alterations. <i>MET</i> exon 14 skipping events occur in both adenocarcinoma and squamous cell carcinoma histology and are found across all smoking histories and histologic types. <i>MET</i> exon 14 skipping results from somatic mutations in the introns of <i>MET and</i> leads to an alternatively spliced transcript of MET<sup><a href="#ref-49">49</a>,<a href="#ref-50">50</a></sup>. The alternatively spliced MET receptor exhibits decreased ubiquitination and delayed downregulation, leading to prolonged activation of MET and MAPK<sup><a href="#ref-49">49</a></sup>. Overall, reports of <i>MET</i> exon 14 skipping have ranged from 1.5% to 6% of NSCLC<sup><a href="#ref-49">49</a>,<a href="#ref-51">51</a>–<a href="#ref-54">54</a></sup>. Patients harboring <i>MET</i> amplification, <i>MET</i> exon 14 alteration, and the combination of both have shown favorable response to MET tyrosine kinase inhibitors such as crizotinib in multiple case series, and these drugs continue to be a topic of ongoing investigation<sup><a href="#ref-54">54</a>–<a href="#ref-58">58</a></sup>.</p></div><div class=section><a name=d2822e485 class=n-a></a><h3 class=section-title>BRAF mutation</h3><p class="" id=d2822e490>BRAF mutations act as an oncogenic driver via the MAPK pathway in NSCLC. The most common of these mutations, BRAF V600E (Val600Glu), is observed in 1 to 2% of lung adenocarcinomas<sup><a href="#ref-3">3</a>,<a href="#ref-59">59</a>–<a href="#ref-61">61</a></sup>. Despite unclear prognostic implications of BRAF V600E mutation, several studies have associated BRAF V600E with poor outcomes and lower response rates to platinum-based chemotherapy in patients with NSCLC compared with patients with NSCLC without BRAF mutations<sup><a href="#ref-61">61</a>,<a href="#ref-62">62</a></sup>. Dabrafenib, a selective BRAF inhibitor, demonstrated clinical activity with an overall confirmed response of 33% (95% CI: 23–45) and median PFS of 5.5 months in patients with previously treated NSCLC with BRAF V600E-mutant NSCLC<sup><a href="#ref-63">63</a></sup>. Additionally, BRAF plus MEK inhibition has demonstrated an increased overall response, PFS, and OS compared with BRAF-inhibitor monotherapy in patients with BRAF V600-mutant metastatic melanoma<sup><a href="#ref-64">64</a>–<a href="#ref-66">66</a></sup>. In a study of 57 patients previously treated with systemic chemotherapy for metastatic BRAF V600E-mutant NSCLC, the investigators showed an overall response of 63.2% (36 of 57, 95% CI: 49.3–75.6) with dabrafenib plus the MEK inhibitor trametinib<sup><a href="#ref-67">67</a></sup>. Investigations targeting BRAF V600E are ongoing.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d2822e529>Anti-angiogenic agents</h2><p class="" id=d2822e532>Angiogenesis is one of the hallmarks of cancer, and blockade of vascular endothelin growth factor receptor-2 (VEGFR-2) signaling inhibits the formation, proliferation, and migration of new blood vessels<sup><a href="#ref-46">46</a></sup>. Bevacizumab, a recombinant humanized monoclonal antibody against VEGF, when compared to carboplatin-paclitaxel first-line chemotherapy, resulted in a notable OS improvement in eligible patients with non-squamous NSCLC<sup><a href="#ref-68">68</a></sup>. The anti-VEGFR antibody ramucirumab is a human IgG1 monoclonal antibody that binds to the VEGFR-2 extracellular domain with high affinity, preventing the binding of all VEGF ligands and receptor activation<sup><a href="#ref-69">69</a></sup>. Ramucirumab improved PFS and OS when combined with docetaxel, irrespective of histology, and was approved by the FDA in NSCLC<sup><a href="#ref-70">70</a></sup>. In a multicenter, double-blind, randomized phase III trial, 1,253 patients with squamous and non-squamous NSCLC who progressed during or after a first-line platinum-based chemotherapy regimen were enrolled. Patients were randomized to receive docetaxel plus either ramucirumab or placebo. Median OS was 10.5 months (IQR: 5.1–21.2) among patients randomized to docetaxel plus ramucirumab and 9.1 months (4.2–18) for patients who received placebo plus docetaxel (hazard ratio [HR]: 0.86, 95% CI: 0.75−0.98, <i>P</i> = 0.023). In those given ramucirumab, median PFS was 4.5 months (IQR: 2.3–8.3), while the control group had a PFS of three months (IQR: 1.4–6.9) (HR: 0.76, 95% CI: 0.68–0.86, <i>P</i> &lt;0.0001)<sup><a href="#ref-71">71</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d2822e565>Immunotherapy in NSCLC</h2><p class="" id=d2822e568>Therapies targeting the complex interaction between tumors and the immune system represent the largest recent breakthrough in cancer therapy. Immunotherapy is a particularly attractive option, as it is independent of the cancer cell mutational status and has been proven to be efficacious with a more acceptable side effect profile. Therapies targeting inhibitory checkpoint molecules including cytotoxic T-lymphocyte-associated protein 4 (CTLA4), programmed death 1 (PD-1), and programmed death ligand 1 (PD-L1) have all demonstrated clinical efficacy. CTLA4 expressed on T cells primarily regulates the extent of the early stages of T-cell activation<sup><a href="#ref-72">72</a></sup>. CTLA4 was the first immune checkpoint receptor to be clinically targeted. The exact mechanism of CTLA4 action is debatable, but its major role is thought to be in the down-modulation of helper T-cell activity and the enhancement of regulatory T-cell immunosuppressive activity<sup><a href="#ref-72">72</a></sup>. Ipilimumab was the first immunotherapeutic to show survival benefit in metastatic melanoma and was approved by the FDA in 2010 for the treatment of advanced melanoma<sup><a href="#ref-73">73</a></sup>. Therapies directed to other immune checkpoint receptors such as PD-1 and PD-L1 have emerged as promising targets. The PD-1 and B7-1 (also known as CD8) receptors, expressed on activated T cells, are connected by ligands PD-L1 and PD-L2, which are expressed by tumor cells and tumor-infiltrating lymphocytes<sup><a href="#ref-74">74</a>–<a href="#ref-76">76</a></sup>. Tumor PD-L1 expression is common in NSCLC. Indeed, in a study of 436 patients with NSCLC, PD-L1 expression was detectable in tumor cells in 34.5% (88/256) of patients with adenocarcinoma and 34% (61/180) of patients with squamous cell carcinoma<sup><a href="#ref-77">77</a></sup>. PD-1 interaction with both PD-L1 and PD-L2 ligands results in tumor immune recognition and elimination escape by inhibiting T-cell activation. The monoclonal antibody nivolumab directed to the PD-1 receptor has shown activity across NSCLCs with various histologic features. In a randomized trial of 272 patients receiving nivolumab versus docetaxel, the median OS was 9.2 months (95% CI: 7.3–13.3) versus 6.0 months (95% CI: 5.1–7.3), respectively<sup><a href="#ref-78">78</a></sup>. The 1-year OS rate was 42% (95% CI: 34–50) with nivolumab versus 24% (95% CI: 17–31) with docetaxel, while the response rate was 20% with nivolumab versus 9% with docetaxel (<i>P</i> = 0.008). Nivolumab resulted in a median PFS of 3.5 months, whereas docetaxel demonstrated a median PFS of 2.8 months (HR for death or disease progression: 0.62, 95% CI: 0.47–0.81, <i>P</i> &lt;0.001).</p><p class="" id=d2822e605>There was a 7% rate of grade 3 or 4 adverse events in the nivolumab group versus 55% in the docetaxel group. In March 2015, nivolumab was approved by the FDA for the management of squamous NSCLC. This was followed by FDA approval of nivolumab for the treatment of non-squamous NSCLC. In October 2015, Borghaei <i>et al.</i> showed that the median OS was 12.2 months (95% CI: 9.7–15.0) among 292 patients in the nivolumab group versus 9.4 months (95% CI: 8.1–10.7) among 290 patients in the docetaxel group (HR for death: 0.73, 96% CI: 0.59–0.89, <i>P</i> = 0.002). At 1 year, the OS rate was 51% with nivolumab versus 39% with docetaxel. At 18 months, the OS rate was 39% (95% CI: 34–45) with nivolumab versus 23% (95% CI: 19–28) with docetaxel<sup><a href="#ref-79">79</a></sup>.</p><p class="" id=d2822e618>In October 2015, another PD-1 receptor-directed monoclonal antibody, pembrolizumab, was approved by the FDA as a second-line treatment in NSCLC. The clinical efficacy of nivolumab and pembrolizumab was found to be independent of histology. Greater benefit was seen in smokers and in patients with PD-L1-positive expression<sup><a href="#ref-78">78</a></sup>. Although the clinical value of targeting the PD-L1-PD-1 pathway has been established, the POPLAR study evaluated the blockade of PD-L1–B7-1 interactions in addition to PD-L1-PD-1 blockade<sup><a href="#ref-77">77</a></sup>. In a multicenter, open-label, phase II, randomized controlled trial by Fehrenbacher <i>et al.</i>, the investigators evaluated the efficacy of atezolizumab versus docetaxel for patients with previously treated NSCLC (POPLAR trial)<sup><a href="#ref-80">80</a></sup>. Atezolizumab is a humanized IgG1 monoclonal anti-PD-L1 antibody which blocks PD-L1-PD-1 and PD-L1-B7-1 interactions, resulting in the restoration of anti-tumor T-cell activity and enhanced T-cell priming. OS in the intention-to-treat population was 12.6 months (95% CI: 9.7–16.4) for atezolizumab versus 9.7 months (95% CI: 8.6–12.0) for docetaxel (HR: 0.73, 95% CI: 0.53–0.99, <i>P</i> = 0.04). The FDA approved atezolizumab in October 2016 for the treatment of patients with metastatic NSCLC whose disease progressed during or following platinum-containing chemotherapy. Several trials comparing anti-PD-1 and anti-PD-L1 agents, individually and in combination with a cytotoxic T-lymphocyte-associated protein 4 inhibitor (ipilimumab), with platinum-based combination regimens as first-line therapy are ongoing<sup><a href="#ref-81">81</a>–<a href="#ref-83">83</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d2822e650>Toxicities in the treatment of NSCLC</h2><p class="" id=d2822e653>Although targeted therapy agents are directed against tumor cells, they are still associated with toxicities affecting multiple organs. Overall, the most common side effects of tyrosine kinase inhibitors and ALK inhibitors involve the gastrointestinal (43–60%), ophthalmic (55–62%), hematologic (5–10%), and cardiovascular (10%) systems<sup><a href="#ref-84">84</a></sup>. A total of 5% of patients discontinued crizotinib use due to toxicity<sup><a href="#ref-85">85</a></sup>. Liver toxicity is more frequent with gefitinib, and diarrhea and skin toxicity are frequent with afatinib. The most common adverse effects observed with ramucirumab were neutropenia (49%), febrile neutropenia (16%), and fatigue (16%). The number of deaths from adverse events was 5%<sup><a href="#ref-86">86</a></sup>.</p><p class="" id=d2822e668>The toxicities of immunotherapies in lung cancer are less frequent. The most commonly observed immune-related adverse effects of nivolumab involved the skin, gastrointestinal tract, and kidneys<sup><a href="#ref-71">71</a></sup>. All adverse effects including pneumonitis were managed effectively with corticosteroids or infliximab and did not result in mortality. Pembrolizumab has a similar safety profile, but one study demonstrated a &lt;1% incidence of mortality from pneumonitis<sup><a href="#ref-84">84</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d2822e682>Radiotherapy</h2><p class="" id=d2822e685>Stereotactic ablative radiotherapy (SABR) has become a treatment option for early stage node-negative NSCLC patients who are not operative candidates or refuse surgical options<sup><a href="#ref-87">87</a></sup>. Despite its high tumor control rate and favorable toxicity profile relative to other surgical and non-surgical options, SABR use has been limited primarily to early stage disease<sup><a href="#ref-87">87</a>–<a href="#ref-90">90</a></sup>. Limited data from two pooled studies demonstrated the potential role for SABR in T1–2aN0M0 inoperable NSCLC<sup><a href="#ref-91">91</a></sup>. Patients were randomized to SABR (31 patients) versus lobectomy (27 patients). The estimated OS at three years was 95% (95% CI: 85–100) in the SABR group compared with 79% (95% CI: 64–97) in the surgery group (HR: 0.14, 95% CI: 0.017–1.190, log-rank <i>P</i> = 0.037). The SABR group had a recurrence-free survival at three years of 86% (95% CI: 74–100), while the surgery group’s was 80% (95% CI: 65–97). In addition to radiotherapy’s role in stage I NSCLC, new studies have examined its role in combination with chemotherapy in the management of stage IV NSCLC and have shown improved survival when radiotherapy was applied to the primary tumor. From a total of 274 patients in a study by Su <i>et al.</i>, 183 had non-oligometastatic disease. Patients with oligometastatic disease who received radiation to primary tumor had better OS (<i>P</i> &lt;0.001). For non-oligometastatic patients, multivariate analysis showed that receiving ≥63 Gy radiation, having a gross tumor volume of &lt;146 cm<sup>3</sup>, having response to chemotherapy, and having stable or increased post-treatment KPS independently predicted better OS (<i>P</i> = 0.018, <i>P</i> = 0.014, <i>P</i> = 0.014, and <i>P</i> = 0.001, respectively). Among patients with greater primary tumor volume, high radiation dose remained of benefit for OS<sup><a href="#ref-92">92</a></sup>. Radiotherapy has also shown benefit in the setting of CNS involvement. Depending on the volume and number of brain metastases, stereotactic radiation is often preferred to whole-brain radiation therapy (WBRT), when feasible, mainly due to fewer neurological side effects. In patients with EGFR-mutant NSCLC with brain metastasis, a higher response rate is noted with WBRT. Additionally, WBRT improves the duration of intracranial disease control compared to tyrosine kinase inhibitors or stereotactic radiosurgery. Despite these results, many practitioners and patients avoid WBRT to prevent the hair loss, fatigue, and neurocognitive sequelae of WBRT<sup><a href="#ref-93">93</a></sup>. In patients with oligo-progressive disease on EGFR tyrosine kinase inhibitor monotherapy, local radiotherapy or surgical resection is recommended with continuation of the EGFR tyrosine kinase inhibitor on a case-by-case basis<sup><a href="#ref-93">93</a>–<a href="#ref-95">95</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d2822e748>Surgical therapy</h2><p class="" id=d2822e751>Various techniques are being investigated to make surgical resection less invasive. Sublobar resection and single-port video-assisted thoracoscopic surgery (VATS) have shown promising results<sup><a href="#ref-96">96</a></sup>. In their study of 121 patients (88% adenocarcinoma, 76% stage I), Hsu <i>et al.</i> used single-port VATS segmentectomies and lobectomies and concluded that resection was both safe and feasible in a multi-institutional retrospective analysis. They identified patient age of 60 years or more, male sex, and tumor size greater than 3 cm as unfavorable preoperative outcome predictors. The results of this study remain to be validated in a randomized controlled prospective study<sup><a href="#ref-96">96</a></sup>. Altorki and colleagues compared patients treated with sublobar resection to patients treated with lobectomy in stage I NSCLC and showed no significant 10-year survival difference among the two groups<sup><a href="#ref-97">97</a></sup>. Additionally, Burdett <i>et al.</i> showed that patients with stage IB, II, or III NSCLC who received chemotherapy following surgery (with or without radiotherapy) had longer survival than those who had surgery without chemotherapy (with or without radiotherapy)<sup><a href="#ref-97">97</a></sup>. The role of surgery has also changed secondary to the implementation of lung cancer screening within and outside the USA.</p><p class="" id=d2822e777>Early cancer detection using low-dose CT screening showed a 20% reduction in lung cancer mortality in the National Lung Screening Trial (NLST)<sup><a href="#ref-98">98</a>,<a href="#ref-99">99</a></sup>. Major goals of surgical participation in lung cancer screening programs were defined and established in Europe by the European Society of Thoracic Surgeons<sup><a href="#ref-100">100</a></sup>. These goals include optimization of the management of screen-detected nodules, reduction of false-positive rates of surgical biopsies, reduction of surgical incision-related trauma, implementation of national or international risk assessment guidelines, implementation of a smoking cessation policy, and active education of primary care physicians towards lung cancer screening programs. Additionally, it is important to emphasize the role of surgical resection in the diagnosis of specific histologic types of lung cancer as per the 2015 World Health Organization (WHO) classification of lung tumors and the eighth edition of the TNM classification. It is emphasized that in tumors such as adenocarcinoma <i>in situ</i> (AIS) and minimally invasive adenocarcinoma (MIA), large cell carcinoma, adenosquamous carcinoma, and pleomorphic carcinoma, the diagnosis cannot be made without complete evaluation of the entire tumor histologically<sup><a href="#ref-101">101</a>,<a href="#ref-102">102</a></sup>. Additionally, although the role of surgery in stage IIIA N2 disease remains controversial, in a meta-analysis of 868 patients from six trials, McElnay <i>et al.</i> showed that the HR comparing patients randomized to surgery after chemotherapy was 1.01 (95% CI: 0.82–1.23, <i>P</i> = 0.954), whereas patients randomized to surgery after chemoradiotherapy demonstrated a HR of 0.87 (95% CI: 0.75–1.01, <i>P</i> = 0.068). The overall HR of all pooled trials was 0.92 (95% CI: 0.81–1.03, <i>P</i> = 0.157)<sup><a href="#ref-103">103</a></sup>. The authors concluded that surgery should be considered as part of the multimodal treatment for patients with resectable lung cancer and ipsilateral mediastinal nodal disease. In the trimodality regimen, a 13% relative improvement in OS was noted with surgical results. Resection for patients with oligometastatic disease represents a relatively new concept in thoracic surgery. In patients with oligometastatic disease, local treatment for distant metastases and curative-intent pulmonary resection may lead to longer survival but requires an optimal method of patient selection. Additional trials are required to determine the ideal treatment plan and long-term follow up in this patient population<sup><a href="#ref-104">104</a>–<a href="#ref-106">106</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d2822e828>Conclusion</h2><p class="" id=d2822e831>The identification of driver mutations has led to a new era of personalized targeted therapy for NSCLC. This has created hope for a disease that carries a high morbidity and mortality. Cutting-edge interrogation of the tumor genome has provided a unique opportunity to investigate potentially targetable molecular aberrations in tumor suppressor genes and oncogenes. Paired with effective targeted therapies, these advances can help improve NSCLC outcomes. However, resistance to targeted therapies and the ongoing demand for better understanding of driver genomic aberrations requires continued and relentless effort. Studies of novel checkpoint inhibitors and numerous trials exploring the role of immunotherapy are ongoing, although there have been promising results with favorable toxicity profiles using immunotherapeutic agents. Combination therapeutics with chemotherapy, immunotherapy, and/or stereotactic ablative therapy need to be studied further.</p></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d2822e1 class=n-a></a><h2 class=main-title id=d3141>Competing interests</h2><p class=metadata-entry><a name=d2822e90 class=n-a></a><p id=d2822e91> No competing interests were disclosed.</p></p></div><div class=back-section><a name=d2822e1 class=n-a></a><h2 class=main-title id=d3143>Grant information</h2><p>This work was supported by National Cancer Institute grant 1U01CA213330-01 (S.N-S).</p><p> <i>The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</i> </p></div><div class=back-section><a name=d2822e838 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading"><span class="f1r-icon icon-79_faculty_recommended_badge red vmiddle default-cursor"></span><span class="prime-red big">F1000 recommended</span></span><h2 class=main-title id=d3508>References</h2><div class="section ref-list"><a name=d2822e838 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a name=d2822e845 class=n-a></a>Downward J: Targeting RAS signalling pathways in cancer therapy. <i>Nat Rev Cancer.</i> 2003; <b>3</b>(1): 11–22. <a target=xrefwindow id=d2822e853 href="http://www.ncbi.nlm.nih.gov/pubmed/12509763">PubMed Abstract </a> | <a target=xrefwindow id=d2822e856 href="http://dx.doi.org/10.1038/nrc969">Publisher Full Text </a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a name=d2822e865 class=n-a></a>Prenzel N, Fischer OM, Streit S, <i> et al.</i>: The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. <i>Endocr Relat Cancer.</i> 2001; <b>8</b>(1): 11–31. <a target=xrefwindow id=d2822e876 href="http://www.ncbi.nlm.nih.gov/pubmed/11350724">PubMed Abstract </a> | <a target=xrefwindow id=d2822e879 href="http://dx.doi.org/10.1677/erc.0.0080011">Publisher Full Text </a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1007413"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2822e888 class=n-a></a>Davies H, Bignell GR, Cox C, <i> et al.</i>: Mutations of the <i>BRAF</i> gene in human cancer. <i>Nature.</i> 2002; <b>417</b>(6892): 949–54. <a target=xrefwindow id=d2822e902 href="http://www.ncbi.nlm.nih.gov/pubmed/12068308">PubMed Abstract </a> | <a target=xrefwindow id=d2822e906 href="http://dx.doi.org/10.1038/nature00766">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1007413">F1000 Recommendation</a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a name=d2822e919 class=n-a></a>Tzahar E, Waterman H, Chen X, <i> et al.</i>: A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. <i>Mol Cell Biol.</i> 1996; <b>16</b>(10): 5276–87. <a target=xrefwindow id=d2822e930 href="http://www.ncbi.nlm.nih.gov/pubmed/8816440">PubMed Abstract </a> | <a target=xrefwindow id=d2822e933 href="http://dx.doi.org/10.1128/MCB.16.10.5276">Publisher Full Text </a> | <a target=xrefwindow id=d2822e937 href="http://www.ncbi.nlm.nih.gov/pmc/articles/231527">Free Full Text </a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a name=d2822e946 class=n-a></a>Sadiq AA, Salgia R: MET as a possible target for non-small-cell lung cancer. <i>J Clin Oncol.</i> 2013; <b>31</b>(8): 1089–96. <a target=xrefwindow id=d2822e954 href="http://www.ncbi.nlm.nih.gov/pubmed/23401458">PubMed Abstract </a> | <a target=xrefwindow id=d2822e957 href="http://dx.doi.org/10.1200/JCO.2012.43.9422">Publisher Full Text </a> | <a target=xrefwindow id=d2822e960 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3589702">Free Full Text </a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/717988102"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2822e970 class=n-a></a>Yu HA, Arcila ME, Rekhtman N, <i> et al.</i>: Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with <i>EGFR</i>-mutant lung cancers. <i>Clin Cancer Res.</i> 2013; <b>19</b>(8): 2240–7. <a target=xrefwindow id=d2822e984 href="http://www.ncbi.nlm.nih.gov/pubmed/23470965">PubMed Abstract </a> | <a target=xrefwindow id=d2822e988 href="http://dx.doi.org/10.1158/1078-0432.CCR-12-2246">Publisher Full Text </a> | <a target=xrefwindow id=d2822e991 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3630270">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/717988102">F1000 Recommendation</a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/13354001"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2822e1004 class=n-a></a>Koivunen JP, Mermel C, Zejnullahu K, <i> et al.</i>: <i>EML4-ALK</i> fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. <i>Clin Cancer Res.</i> 2008; <b>14</b>(13): 4275–83. <a target=xrefwindow id=d2822e1018 href="http://www.ncbi.nlm.nih.gov/pubmed/18594010">PubMed Abstract </a> | <a target=xrefwindow id=d2822e1022 href="http://dx.doi.org/10.1158/1078-0432.CCR-08-0168">Publisher Full Text </a> | <a target=xrefwindow id=d2822e1025 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3025451">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/13354001">F1000 Recommendation</a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1018878"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2822e1038 class=n-a></a>Lynch TJ, Bell DW, Sordella R, <i> et al.</i>: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. <i>N Engl J Med.</i> 2004; <b>350</b>(21): 2129–39. <a target=xrefwindow id=d2822e1049 href="http://www.ncbi.nlm.nih.gov/pubmed/15118073">PubMed Abstract </a> | <a target=xrefwindow id=d2822e1052 href="http://dx.doi.org/10.1056/NEJMoa040938">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1018878">F1000 Recommendation</a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a name=d2822e1065 class=n-a></a>Cadranel J, Ruppert A, Beau-Faller M, <i> et al.</i>: Therapeutic strategy for advanced EGFR mutant non-small-cell lung carcinoma. <i>Crit Rev Oncol Hematol.</i> 2013; <b>88</b>(3): 477–93. <a target=xrefwindow id=d2822e1076 href="http://www.ncbi.nlm.nih.gov/pubmed/23911281">PubMed Abstract </a> | <a target=xrefwindow id=d2822e1079 href="http://dx.doi.org/10.1016/j.critrevonc.2013.06.009">Publisher Full Text </a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a name=d2822e1088 class=n-a></a>Russell PA, Barnett SA, Walkiewicz M, <i> et al.</i>: Correlation of mutation status and survival with predominant histologic subtype according to the new IASLC/ATS/ERS lung adenocarcinoma classification in stage III (N2) patients. <i>J Thorac Oncol.</i> 2013; <b>8</b>(4): 461–8. <a target=xrefwindow id=d2822e1099 href="http://www.ncbi.nlm.nih.gov/pubmed/23486266">PubMed Abstract </a> | <a target=xrefwindow id=d2822e1102 href="http://dx.doi.org/10.1097/JTO.0b013e3182828fb8">Publisher Full Text </a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a name=d2822e1111 class=n-a></a>Tokumo M, Toyooka S, Kiura K, <i> et al.</i>: The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. <i>Clin Cancer Res.</i> 2005; <b>11</b>(3): 1167–73. <a target=xrefwindow id=d2822e1122 href="http://www.ncbi.nlm.nih.gov/pubmed/15709185">PubMed Abstract </a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a name=d2822e1132 class=n-a></a>Kosaka T, Yatabe Y, Endoh H, <i> et al.</i>: Mutations of the <i>epidermal growth factor receptor</i> gene in lung cancer: biological and clinical implications. <i>Cancer Res.</i> 2004; <b>64</b>(24): 8919–23. <a target=xrefwindow id=d2822e1146 href="http://www.ncbi.nlm.nih.gov/pubmed/15604253">PubMed Abstract </a> | <a target=xrefwindow id=d2822e1150 href="http://dx.doi.org/10.1158/0008-5472.CAN-04-2818">Publisher Full Text </a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a name=d2822e1159 class=n-a></a>Pao W, Miller VA: Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. <i>J Clin Oncol.</i> 2005; <b>23</b>(11): 2556–68. <a target=xrefwindow id=d2822e1167 href="http://www.ncbi.nlm.nih.gov/pubmed/15767641">PubMed Abstract </a> | <a target=xrefwindow id=d2822e1170 href="http://dx.doi.org/10.1200/JCO.2005.07.799">Publisher Full Text </a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a name=d2822e1179 class=n-a></a>Wu YL, Zhong WZ, Li LY, <i> et al.</i>: Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in mainland China. <i>J Thorac Oncol.</i> 2007; <b>2</b>(5): 430–9. <a target=xrefwindow id=d2822e1190 href="http://www.ncbi.nlm.nih.gov/pubmed/17473659">PubMed Abstract </a> | <a target=xrefwindow id=d2822e1193 href="http://dx.doi.org/10.1097/01.JTO.0000268677.87496.4c">Publisher Full Text </a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1164675"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2822e1202 class=n-a></a>Mok TS, Wu YL, Thongprasert S, <i> et al.</i>: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. <i>N Engl J Med.</i> 2009; <b>361</b>(10): 947–57. <a target=xrefwindow id=d2822e1213 href="http://www.ncbi.nlm.nih.gov/pubmed/19692680">PubMed Abstract </a> | <a target=xrefwindow id=d2822e1216 href="http://dx.doi.org/10.1056/NEJMoa0810699">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1164675">F1000 Recommendation</a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a name=d2822e1229 class=n-a></a>Socinski MA, Evans T, Gettinger S, <i> et al.</i>: Treatment of stage IV non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. <i>Chest.</i> 2013; <b>143</b>(5 Suppl): e341S–e368S. <a target=xrefwindow id=d2822e1240 href="http://www.ncbi.nlm.nih.gov/pubmed/23649446">PubMed Abstract </a> | <a target=xrefwindow id=d2822e1243 href="http://dx.doi.org/10.1378/chest.12-2361">Publisher Full Text </a> | <a target=xrefwindow id=d2822e1247 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4694611">Free Full Text </a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a name=d2822e1256 class=n-a></a>Balak MN, Gong Y, Riely GJ, <i> et al.</i>: Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. <i>Clin Cancer Res.</i> 2006; <b>12</b>(21): 6494–501. <a target=xrefwindow id=d2822e1267 href="http://www.ncbi.nlm.nih.gov/pubmed/17085664">PubMed Abstract </a> | <a target=xrefwindow id=d2822e1270 href="http://dx.doi.org/10.1158/1078-0432.CCR-06-1570">Publisher Full Text </a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1668958"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2822e1280 class=n-a></a>Zhou W, Ercan D, Chen L, <i> et al.</i>: Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. <i>Nature.</i> 2009; <b>462</b>(7276): 1070–4. <a target=xrefwindow id=d2822e1291 href="http://www.ncbi.nlm.nih.gov/pubmed/20033049">PubMed Abstract </a> | <a target=xrefwindow id=d2822e1294 href="http://dx.doi.org/10.1038/nature08622">Publisher Full Text </a> | <a target=xrefwindow id=d2822e1298 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2879581">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1668958">F1000 Recommendation</a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a name=d2822e1311 class=n-a></a>Ramalingam S, Yang JC, Lee CK, <i> et al.</i>: LBA1_PR: Osimertinib as first-line treatment for EGFR mutation-positive advanced NSCLC: updated efficacy and safety results from two Phase I expansion cohorts. <i>J Thorac Oncol.</i> 2016; <b>11</b>(4 Suppl): S152. <a target=xrefwindow id=d2822e1322 href="http://www.ncbi.nlm.nih.gov/pubmed/27198352">PubMed Abstract </a> | <a target=xrefwindow id=d2822e1325 href="http://dx.doi.org/10.1016/S1556-0864(16)30324-0">Publisher Full Text </a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a name=d2822e1334 class=n-a></a>Jänne PA, Yang JC, Kim DW, <i> et al.</i>: AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. <i>N Engl J Med.</i> 2015; <b>372</b>(18): 1689–99. <a target=xrefwindow id=d2822e1345 href="http://www.ncbi.nlm.nih.gov/pubmed/25923549">PubMed Abstract </a> | <a target=xrefwindow id=d2822e1348 href="http://dx.doi.org/10.1056/NEJMoa1411817">Publisher Full Text </a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a name=d2822e1357 class=n-a></a>Goss G, Tsai C, Shepherd FA, <i> et al.</i>: Osimertinib for pretreated <i>EGFR</i> Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study. <i>Lancet Oncol.</i> 2016; <b>17</b>(12): 1643–52. <a target=xrefwindow id=d2822e1371 href="http://www.ncbi.nlm.nih.gov/pubmed/27751847">PubMed Abstract </a> | <a target=xrefwindow id=d2822e1375 href="http://dx.doi.org/10.1016/S1470-2045(16)30508-3">Publisher Full Text </a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a name=d2822e1384 class=n-a></a>Sequist LV, Heist RS, Shaw AT, <i> et al.</i>: Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. <i>Ann Oncol.</i> 2011; <b>22</b>(12): 2616–24. <a target=xrefwindow id=d2822e1395 href="http://www.ncbi.nlm.nih.gov/pubmed/22071650">PubMed Abstract </a> | <a target=xrefwindow id=d2822e1398 href="http://dx.doi.org/10.1093/annonc/mdr489">Publisher Full Text </a> | <a target=xrefwindow id=d2822e1402 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3493130">Free Full Text </a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a name=d2822e1411 class=n-a></a>Thatcher N, Hirsch FR, Luft AV, <i> et al.</i>: Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. <i>Lancet Oncol.</i> 2015; <b>16</b>(7): 763–74. <a target=xrefwindow id=d2822e1422 href="http://www.ncbi.nlm.nih.gov/pubmed/26045340">PubMed Abstract </a> | <a target=xrefwindow id=d2822e1425 href="http://dx.doi.org/10.1016/S1470-2045(15)00021-2">Publisher Full Text </a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a name=d2822e1435 class=n-a></a>Choi YL, Soda M, Yamashita Y, <i> et al.</i>: EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. <i>N Engl J Med.</i> 2010; <b>363</b>(18): 1734–9. <a target=xrefwindow id=d2822e1446 href="http://www.ncbi.nlm.nih.gov/pubmed/20979473">PubMed Abstract </a> | <a target=xrefwindow id=d2822e1449 href="http://dx.doi.org/10.1056/NEJMoa1007478">Publisher Full Text </a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/13353988"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2822e1458 class=n-a></a>Soda M, Choi YL, Enomoto M, <i> et al.</i>: Identification of the transforming <i>EML4-ALK</i> fusion gene in non-small-cell lung cancer. <i>Nature.</i> 2007; <b>448</b>(7153): 561–6. <a target=xrefwindow id=d2822e1472 href="http://www.ncbi.nlm.nih.gov/pubmed/17625570">PubMed Abstract </a> | <a target=xrefwindow id=d2822e1476 href="http://dx.doi.org/10.1038/nature05945">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/13353988">F1000 Recommendation</a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a name=d2822e1489 class=n-a></a>Shaw AT, Engelman JA: ALK in lung cancer: past, present, and future. <i>J Clin Oncol.</i> 2013; <b>31</b>(8): 1105–11. <a target=xrefwindow id=d2822e1497 href="http://www.ncbi.nlm.nih.gov/pubmed/23401436">PubMed Abstract </a> | <a target=xrefwindow id=d2822e1500 href="http://dx.doi.org/10.1200/JCO.2012.44.5353">Publisher Full Text </a> | <a target=xrefwindow id=d2822e1503 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4209068">Free Full Text </a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a name=d2822e1512 class=n-a></a>Camidge DR, Bang Y, Kwak EL, <i> et al.</i>: Activity and safety of crizotinib in patients with <i>ALK</i>-positive non-small-cell lung cancer: updated results from a phase 1 study. <i>Lancet Oncol.</i> 2012; <b>13</b>(10): 1011–9. <a target=xrefwindow id=d2822e1526 href="http://www.ncbi.nlm.nih.gov/pubmed/22954507">PubMed Abstract </a> | <a target=xrefwindow id=d2822e1530 href="http://dx.doi.org/10.1016/S1470-2045(12)70344-3">Publisher Full Text </a> | <a target=xrefwindow id=d2822e1533 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3936578">Free Full Text </a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a name=d2822e1542 class=n-a></a>Ou SH, Kwak EL, Siwak-Tapp C, <i> et al.</i>: Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with <i>de novo MET</i> amplification. <i>J Thorac Oncol.</i> 2011; <b>6</b>(5): 942–6. <a target=xrefwindow id=d2822e1556 href="http://www.ncbi.nlm.nih.gov/pubmed/21623265">PubMed Abstract </a> | <a target=xrefwindow id=d2822e1560 href="http://dx.doi.org/10.1097/JTO.0b013e31821528d3">Publisher Full Text </a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a name=d2822e1569 class=n-a></a>Shaw AT, Yeap BY, Solomon BJ, <i> et al.</i>: Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring <i>ALK</i> gene rearrangement: a retrospective analysis. <i>Lancet Oncol.</i> 2011; <b>12</b>(11): 1004–12. <a target=xrefwindow id=d2822e1583 href="http://www.ncbi.nlm.nih.gov/pubmed/21933749">PubMed Abstract </a> | <a target=xrefwindow id=d2822e1587 href="http://dx.doi.org/10.1016/S1470-2045(11)70232-7">Publisher Full Text </a> | <a target=xrefwindow id=d2822e1590 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3328296">Free Full Text </a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a name=d2822e1600 class=n-a></a>Blackhall F, Kim D, Besse B, <i> et al.</i>: Patient-reported outcomes and quality of life in PROFILE 1007: a randomized trial of crizotinib compared with chemotherapy in previously treated patients with <i>ALK</i>-positive advanced non-small-cell lung cancer. <i>J Thorac Oncol.</i> 2014; <b>9</b>(11): 1625–33. <a target=xrefwindow id=d2822e1614 href="http://www.ncbi.nlm.nih.gov/pubmed/25436797">PubMed Abstract </a> | <a target=xrefwindow id=d2822e1618 href="http://dx.doi.org/10.1097/JTO.0000000000000318">Publisher Full Text </a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a name=d2822e1627 class=n-a></a>Doebele RC, Pilling AB, Aisner DL, <i> et al.</i>: Mechanisms of resistance to crizotinib in patients with <i>ALK</i> gene rearranged non-small cell lung cancer. <i>Clin Cancer Res.</i> 2012; <b>18</b>(5): 1472–82. <a target=xrefwindow id=d2822e1641 href="http://www.ncbi.nlm.nih.gov/pubmed/22235099">PubMed Abstract </a> | <a target=xrefwindow id=d2822e1645 href="http://dx.doi.org/10.1158/1078-0432.CCR-11-2906">Publisher Full Text </a> | <a target=xrefwindow id=d2822e1648 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3311875">Free Full Text </a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a name=d2822e1657 class=n-a></a>Katayama R, Shaw AT, Khan TM, <i> et al.</i>: Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. <i>Sci Transl Med.</i> 2012; <b>4</b>(120): 120ra17. <a target=xrefwindow id=d2822e1668 href="http://www.ncbi.nlm.nih.gov/pubmed/22277784">PubMed Abstract </a> | <a target=xrefwindow id=d2822e1671 href="http://dx.doi.org/10.1126/scitranslmed.3003316">Publisher Full Text </a> | <a target=xrefwindow id=d2822e1675 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3385512">Free Full Text </a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718326531"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2822e1684 class=n-a></a>Shaw AT, Kim D, Mehra R, <i> et al.</i>: Ceritinib in <i>ALK</i>-rearranged non-small-cell lung cancer. <i>N Engl J Med.</i> 2014; <b>370</b>(13): 1189–97. <a target=xrefwindow id=d2822e1698 href="http://www.ncbi.nlm.nih.gov/pubmed/24670165">PubMed Abstract </a> | <a target=xrefwindow id=d2822e1702 href="http://dx.doi.org/10.1056/NEJMoa1311107">Publisher Full Text </a> | <a target=xrefwindow id=d2822e1705 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4079055">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718326531">F1000 Recommendation</a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a name=d2822e1718 class=n-a></a>Ou SH, Ahn JS, De Petris L, <i> et al.</i>: Alectinib in Crizotinib-Refractory <i>ALK</i>-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study. <i>J Clin Oncol.</i> 2016; <b>34</b>(7): 661–8. <a target=xrefwindow id=d2822e1732 href="http://www.ncbi.nlm.nih.gov/pubmed/26598747">PubMed Abstract </a> | <a target=xrefwindow id=d2822e1736 href="http://dx.doi.org/10.1200/JCO.2015.63.9443">Publisher Full Text </a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a name=d2822e1745 class=n-a></a>Kim D, Mehra R, Tan DS, <i> et al.</i>: Activity and safety of ceritinib in patients with <i>ALK</i>-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial. <i>Lancet Oncol.</i> 2016; <b>17</b>(4): 452–63. <a target=xrefwindow id=d2822e1759 href="http://www.ncbi.nlm.nih.gov/pubmed/26973324">PubMed Abstract </a> | <a target=xrefwindow id=d2822e1763 href="http://dx.doi.org/10.1016/S1470-2045(15)00614-2">Publisher Full Text </a> | <a target=xrefwindow id=d2822e1766 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5063047">Free Full Text </a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a name=d2822e1776 class=n-a></a>Felip E, Bauer TM, Solomon B, <i> et al.</i>: Safety and efficacy of lorlatinib (PF-06463922) in patients with advanced ALK+ or ROS1+ non-small-cell lung cancer (NSCLC). <i>J Thorac Oncol.</i> Presented at: 17th World Conference on Lung Cancer; Vienna, Austria. Abstract MA07.11. 2017; <b>12</b>(1): S383–S384. <a target=xrefwindow id=d2822e1787 href="http://dx.doi.org/10.1016/j.jtho.2016.11.433">Publisher Full Text </a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1138854"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2822e1796 class=n-a></a>Ding L, Getz G, Wheeler DA, <i> et al.</i>: Somatic mutations affect key pathways in lung adenocarcinoma. <i>Nature.</i> 2008; <b>455</b>(7216): 1069–75. <a target=xrefwindow id=d2822e1807 href="http://www.ncbi.nlm.nih.gov/pubmed/18948947">PubMed Abstract </a> | <a target=xrefwindow id=d2822e1810 href="http://dx.doi.org/10.1038/nature07423">Publisher Full Text </a> | <a target=xrefwindow id=d2822e1814 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2694412">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1138854">F1000 Recommendation</a></span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a name=d2822e1827 class=n-a></a>Riely GJ, Kris MG, Rosenbaum D, <i> et al.</i>: Frequency and distinctive spectrum of <i>KRAS</i> mutations in never smokers with lung adenocarcinoma. <i>Clin Cancer Res.</i> 2008; <b>14</b>(18): 5731–4. <a target=xrefwindow id=d2822e1841 href="http://www.ncbi.nlm.nih.gov/pubmed/18794081">PubMed Abstract </a> | <a target=xrefwindow id=d2822e1845 href="http://dx.doi.org/10.1158/1078-0432.CCR-08-0646">Publisher Full Text </a> | <a target=xrefwindow id=d2822e1848 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2754127">Free Full Text </a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a name=d2822e1857 class=n-a></a>Yip PY, Yu B, Cooper WA, <i> et al.</i>: Patterns of DNA mutations and <i>ALK</i> rearrangement in resected node negative lung adenocarcinoma. <i>J Thorac Oncol.</i> 2013; <b>8</b>(4): 408–14. <a target=xrefwindow id=d2822e1871 href="http://www.ncbi.nlm.nih.gov/pubmed/23392229">PubMed Abstract </a> | <a target=xrefwindow id=d2822e1875 href="http://dx.doi.org/10.1097/JTO.0b013e318283558e">Publisher Full Text </a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a name=d2822e1884 class=n-a></a>Tao Z, Le Blanc JM, Wang C, <i> et al.</i>: Coadministration of Trametinib and Palbociclib Radiosensitizes KRAS-Mutant Non-Small Cell Lung Cancers <i>In Vitro</i> and <i>In Vivo</i>. <i>Clin Cancer Res.</i> 2016; <b>22</b>(1): 122–33. <a target=xrefwindow id=d2822e1902 href="http://www.ncbi.nlm.nih.gov/pubmed/26728409">PubMed Abstract </a> | <a target=xrefwindow id=d2822e1905 href="http://dx.doi.org/10.1158/1078-0432.CCR-15-0589">Publisher Full Text </a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a name=d2822e1914 class=n-a></a>Puyol M, Martín A, Dubus P, <i> et al.</i>: A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma. <i>Cancer Cell.</i> 2010; <b>18</b>(1): 63–73. <a target=xrefwindow id=d2822e1925 href="http://www.ncbi.nlm.nih.gov/pubmed/20609353">PubMed Abstract </a> | <a target=xrefwindow id=d2822e1928 href="http://dx.doi.org/10.1016/j.ccr.2010.05.025">Publisher Full Text </a></span></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a name=d2822e1938 class=n-a></a>Davies KD, Doebele RC: Molecular pathways: ROS1 fusion proteins in cancer. <i>Clin Cancer Res.</i> 2013; <b>19</b>(15): 4040–5. <a target=xrefwindow id=d2822e1946 href="http://www.ncbi.nlm.nih.gov/pubmed/23719267">PubMed Abstract </a> | <a target=xrefwindow id=d2822e1949 href="http://dx.doi.org/10.1158/1078-0432.CCR-12-2851">Publisher Full Text </a> | <a target=xrefwindow id=d2822e1952 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3732549">Free Full Text </a></span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a name=d2822e1961 class=n-a></a>Clavé S, Gimeno J, Muñoz-Mármol AM, <i> et al.</i>: <i>ROS1</i> copy number alterations are frequent in non-small cell lung cancer. <i>Oncotarget.</i> 2016; <b>7</b>(7): 8019–8028. <a target=xrefwindow id=d2822e1975 href="http://www.ncbi.nlm.nih.gov/pubmed/26783962">PubMed Abstract </a> | <a target=xrefwindow id=d2822e1979 href="http://dx.doi.org/10.18632/oncotarget.6921">Publisher Full Text </a> | <a target=xrefwindow id=d2822e1982 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4884972">Free Full Text </a></span></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a name=d2822e1991 class=n-a></a>Gainor JF, Shaw AT: Novel targets in non-small cell lung cancer: <i>ROS1</i> and <i>RET</i> fusions. <i>Oncologist.</i> 2013; <b>18</b>(7): 865–75. <a target=xrefwindow id=d2822e2005 href="http://www.ncbi.nlm.nih.gov/pubmed/23814043">PubMed Abstract </a> | <a target=xrefwindow id=d2822e2009 href="http://dx.doi.org/10.1634/theoncologist.2013-0095">Publisher Full Text </a> | <a target=xrefwindow id=d2822e2012 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3720641">Free Full Text </a></span></li><li><a name=ref-45 class=n-a></a><span class=label>45. </span>&nbsp;<span class=citation><a name=d2822e2021 class=n-a></a>Bergethon K, Shaw AT, Ou SH, <i> et al.</i>: <i>ROS1</i> rearrangements define a unique molecular class of lung cancers. <i>J Clin Oncol.</i> 2012; <b>30</b>(8): 863–70. <a target=xrefwindow id=d2822e2035 href="http://www.ncbi.nlm.nih.gov/pubmed/22215748">PubMed Abstract </a> | <a target=xrefwindow id=d2822e2039 href="http://dx.doi.org/10.1200/JCO.2011.35.6345">Publisher Full Text </a> | <a target=xrefwindow id=d2822e2042 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3295572">Free Full Text </a></span></li><li><a name=ref-46 class=n-a></a><span class=label>46. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718337007"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2822e2051 class=n-a></a>Huber KV, Salah E, Radic B, <i> et al.</i>: Stereospecific targeting of MTH1 by (<i>S</i>)-crizotinib as an anticancer strategy. <i>Nature.</i> 2014; <b>508</b>(7495): 222–7. <a target=xrefwindow id=d2822e2065 href="http://www.ncbi.nlm.nih.gov/pubmed/24695225">PubMed Abstract </a> | <a target=xrefwindow id=d2822e2069 href="http://dx.doi.org/10.1038/nature13194">Publisher Full Text </a> | <a target=xrefwindow id=d2822e2072 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4150021">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718337007">F1000 Recommendation</a></span></li><li><a name=ref-47 class=n-a></a><span class=label>47. </span>&nbsp;<span class=citation><a name=d2822e2085 class=n-a></a>Shaw AT, Ou SH, Bang YJ, <i> et al.</i>: Crizotinib in <i>ROS1</i>-rearranged non-small-cell lung cancer. <i>N Engl J Med.</i> 2014; <b>371</b>(21): 1963–71. <a target=xrefwindow id=d2822e2099 href="http://www.ncbi.nlm.nih.gov/pubmed/25264305">PubMed Abstract </a> | <a target=xrefwindow id=d2822e2103 href="http://dx.doi.org/10.1056/NEJMoa1406766">Publisher Full Text </a> | <a target=xrefwindow id=d2822e2106 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4264527">Free Full Text </a></span></li><li><a name=ref-48 class=n-a></a><span class=label>48. </span>&nbsp;<span class=citation><a name=d2822e2116 class=n-a></a>Gao J, Aksoy BA, Dogrusoz U, <i> et al.</i>: Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. <i>Sci Signal.</i> 2013; <b>6</b>(269): pl1. <a target=xrefwindow id=d2822e2127 href="http://www.ncbi.nlm.nih.gov/pubmed/23550210">PubMed Abstract </a> | <a target=xrefwindow id=d2822e2130 href="http://dx.doi.org/10.1126/scisignal.2004088">Publisher Full Text </a> | <a target=xrefwindow id=d2822e2134 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4160307">Free Full Text </a></span></li><li><a name=ref-49 class=n-a></a><span class=label>49. </span>&nbsp;<span class=citation><a name=d2822e2143 class=n-a></a>Krishnaswamy S, Kanteti R, Duke-Cohan JS, <i> et al.</i>: Ethnic differences and functional analysis of MET mutations in lung cancer. <i>Clin Cancer Res.</i> 2009; <b>15</b>(18): 5714–23. <a target=xrefwindow id=d2822e2154 href="http://www.ncbi.nlm.nih.gov/pubmed/19723643">PubMed Abstract </a> | <a target=xrefwindow id=d2822e2157 href="http://dx.doi.org/10.1158/1078-0432.CCR-09-0070">Publisher Full Text </a> | <a target=xrefwindow id=d2822e2161 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2767337">Free Full Text </a></span></li><li><a name=ref-50 class=n-a></a><span class=label>50. </span>&nbsp;<span class=citation><a name=d2822e2170 class=n-a></a>Kong-Beltran M, Seshagiri S, Zha J, <i> et al.</i>: Somatic mutations lead to an oncogenic deletion of met in lung cancer. <i>Cancer Res.</i> 2006; <b>66</b>(1): 283–9. <a target=xrefwindow id=d2822e2181 href="http://www.ncbi.nlm.nih.gov/pubmed/16397241">PubMed Abstract </a> | <a target=xrefwindow id=d2822e2184 href="http://dx.doi.org/10.1158/0008-5472.CAN-05-2749">Publisher Full Text </a></span></li><li><a name=ref-51 class=n-a></a><span class=label>51. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1025412"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2822e2193 class=n-a></a>Ma PC, Jagadeeswaran R, Jagadeesh S, <i> et al.</i>: Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. <i>Cancer Res.</i> 2005; <b>65</b>(4): 1479–88. <a target=xrefwindow id=d2822e2204 href="http://www.ncbi.nlm.nih.gov/pubmed/15735036">PubMed Abstract </a> | <a target=xrefwindow id=d2822e2207 href="http://dx.doi.org/10.1158/0008-5472.CAN-04-2650">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1025412">F1000 Recommendation</a></span></li><li><a name=ref-52 class=n-a></a><span class=label>52. </span>&nbsp;<span class=citation><a name=d2822e2220 class=n-a></a>Seo JS, Ju YS, Lee WC, <i> et al.</i>: The transcriptional landscape and mutational profile of lung adenocarcinoma. <i>Genome Res.</i> 2012; <b>22</b>(11): 2109–19. <a target=xrefwindow id=d2822e2231 href="http://www.ncbi.nlm.nih.gov/pubmed/22975805">PubMed Abstract </a> | <a target=xrefwindow id=d2822e2234 href="http://dx.doi.org/10.1101/gr.145144.112">Publisher Full Text </a> | <a target=xrefwindow id=d2822e2238 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3483540">Free Full Text </a></span></li><li><a name=ref-53 class=n-a></a><span class=label>53. </span>&nbsp;<span class=citation><a name=d2822e2247 class=n-a></a>Cancer Genome Atlas Research Network: Comprehensive molecular profiling of lung adenocarcinoma. <i>Nature.</i> 2014; <b>511</b>(7511): 543–50. <a target=xrefwindow id=d2822e2255 href="http://www.ncbi.nlm.nih.gov/pubmed/25079552">PubMed Abstract </a> | <a target=xrefwindow id=d2822e2258 href="http://dx.doi.org/10.1038/nature13385">Publisher Full Text </a> | <a target=xrefwindow id=d2822e2261 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4231481">Free Full Text </a></span></li><li><a name=ref-54 class=n-a></a><span class=label>54. </span>&nbsp;<span class=citation><a name=d2822e2271 class=n-a></a>Frampton GM, Ali SM, Rosenzweig M, <i> et al.</i>: Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. <i>Cancer Discov.</i> 2015; <b>5</b>(8): 850–9. <a target=xrefwindow id=d2822e2282 href="http://www.ncbi.nlm.nih.gov/pubmed/25971938">PubMed Abstract </a> | <a target=xrefwindow id=d2822e2285 href="http://dx.doi.org/10.1158/2159-8290.CD-15-0285">Publisher Full Text </a></span></li><li><a name=ref-55 class=n-a></a><span class=label>55. </span>&nbsp;<span class=citation><a name=d2822e2294 class=n-a></a>Awad MM, Oxnard GR, Jackman DM, <i> et al.</i>: <i>MET</i> Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent <i>MET</i> Genomic Amplification and c-Met Overexpression. <i>J Clin Oncol.</i> 2016; <b>34</b>(7): 721–30. <a target=xrefwindow id=d2822e2312 href="http://www.ncbi.nlm.nih.gov/pubmed/26729443">PubMed Abstract </a> | <a target=xrefwindow id=d2822e2315 href="http://dx.doi.org/10.1200/JCO.2015.63.4600">Publisher Full Text </a></span></li><li><a name=ref-56 class=n-a></a><span class=label>56. </span>&nbsp;<span class=citation><a name=d2822e2324 class=n-a></a>Caparica R, Yen CT, Coudry R, <i> et al.</i>: Responses to Crizotinib Can Occur in High-Level <i>MET</i>-Amplified Non-Small Cell Lung Cancer Independent of <i>MET</i> Exon 14 Alterations. <i>J Thorac Oncol.</i> 2017; <b>12</b>(1): 141–4. <a target=xrefwindow id=d2822e2342 href="http://www.ncbi.nlm.nih.gov/pubmed/27664533">PubMed Abstract </a> | <a target=xrefwindow id=d2822e2345 href="http://dx.doi.org/10.1016/j.jtho.2016.09.116">Publisher Full Text </a></span></li><li><a name=ref-57 class=n-a></a><span class=label>57. </span>&nbsp;<span class=citation><a name=d2822e2354 class=n-a></a>Wang SX, Zhang B, Wakelee HA, <i> et al.</i>: Case Series of MET Exon 14 Skipping Mutation-positive Non-Small Cell Lung Cancers and Response to Crizotinib. <i>Int J Radiat Oncol Biol Phys.</i> 2017; <b>98</b>(1): 239. <a target=xrefwindow id=d2822e2365 href="http://www.ncbi.nlm.nih.gov/pubmed/28587017">PubMed Abstract </a> | <a target=xrefwindow id=d2822e2368 href="http://dx.doi.org/10.1016/j.ijrobp.2017.01.170">Publisher Full Text </a></span></li><li><a name=ref-58 class=n-a></a><span class=label>58. </span>&nbsp;<span class=citation><a name=d2822e2377 class=n-a></a>Noonan SA, Berry L, Lu X, <i> et al.</i>: Identifying the Appropriate FISH Criteria for Defining <i>MET</i> Copy Number-Driven Lung Adenocarcinoma through Oncogene Overlap Analysis. <i>J Thorac Oncol.</i> 2016; <b>11</b>(8): 1293–304. <a target=xrefwindow id=d2822e2391 href="http://www.ncbi.nlm.nih.gov/pubmed/27262212">PubMed Abstract </a> | <a target=xrefwindow id=d2822e2395 href="http://dx.doi.org/10.1016/j.jtho.2016.04.033">Publisher Full Text </a> | <a target=xrefwindow id=d2822e2398 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5404374">Free Full Text </a></span></li><li><a name=ref-59 class=n-a></a><span class=label>59. </span>&nbsp;<span class=citation><a name=d2822e2407 class=n-a></a>Camidge DR, Ignatius Ou SH, Shapiro G, <i> et al.</i>: Efficacy and safety of crizotinib in patients with advanced <i>c-MET</i>-amplified non-small cell lung cancer (NSCLC). <i>J Clin Oncol.</i> 2014; <b>32</b>(suppl 5): 8001. <a target=xrefwindow id=d2822e2421 href="http://ascopubs.org/doi/abs/10.1200/jco.2014.32.15_suppl.8001">Reference Source</a></span></li><li><a name=ref-60 class=n-a></a><span class=label>60. </span>&nbsp;<span class=citation><a name=d2822e2431 class=n-a></a>Mazières J, Merlio J, Missy P, <i> et al.</i>: Routine molecular profiling of patients with NSCLC - Authors' reply. <i>Lancet.</i> 2016; <b>388</b>(10049): 1054–5. <a target=xrefwindow id=d2822e2442 href="http://www.ncbi.nlm.nih.gov/pubmed/27628516">PubMed Abstract </a> | <a target=xrefwindow id=d2822e2445 href="http://dx.doi.org/10.1016/S0140-6736(16)31136-9">Publisher Full Text </a></span></li><li><a name=ref-61 class=n-a></a><span class=label>61. </span>&nbsp;<span class=citation><a name=d2822e2454 class=n-a></a>Kris MG, Johnson BE, Berry LD, <i> et al.</i>: Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. <i>JAMA.</i> 2014; <b>311</b>(19): 1998–2006. <a target=xrefwindow id=d2822e2465 href="http://www.ncbi.nlm.nih.gov/pubmed/24846037">PubMed Abstract </a> | <a target=xrefwindow id=d2822e2468 href="http://dx.doi.org/10.1001/jama.2014.3741">Publisher Full Text </a> | <a target=xrefwindow id=d2822e2472 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4163053">Free Full Text </a></span></li><li><a name=ref-62 class=n-a></a><span class=label>62. </span>&nbsp;<span class=citation><a name=d2822e2480 class=n-a></a>Cardarella S, Ogino A, Nishino M, <i> et al.</i>: Clinical, pathologic, and biologic features associated with <i>BRAF</i> mutations in non-small cell lung cancer. <i>Clin Cancer Res.</i> 2013; <b>19</b>(16): 4532–40. <a target=xrefwindow id=d2822e2494 href="http://www.ncbi.nlm.nih.gov/pubmed/23833300">PubMed Abstract </a> | <a target=xrefwindow id=d2822e2498 href="http://dx.doi.org/10.1158/1078-0432.CCR-13-0657">Publisher Full Text </a> | <a target=xrefwindow id=d2822e2501 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3762878">Free Full Text </a></span></li><li><a name=ref-63 class=n-a></a><span class=label>63. </span>&nbsp;<span class=citation><a name=d2822e2510 class=n-a></a>Marchetti A, Felicioni L, Malatesta S, <i> et al.</i>: Clinical features and outcome of patients with non-small-cell lung cancer harboring <i>BRAF</i> mutations. <i>J Clin Oncol.</i> 2011; <b>29</b>(26): 3574–9. <a target=xrefwindow id=d2822e2524 href="http://www.ncbi.nlm.nih.gov/pubmed/21825258">PubMed Abstract </a> | <a target=xrefwindow id=d2822e2528 href="http://dx.doi.org/10.1200/JCO.2011.35.9638">Publisher Full Text </a></span></li><li><a name=ref-64 class=n-a></a><span class=label>64. </span>&nbsp;<span class=citation><a name=d2822e2537 class=n-a></a>Planchard D, Kim TM, Mazieres J, <i> et al.</i>: Dabrafenib in patients with <i>BRAF</i><sup>V600E</sup>-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial. <i>Lancet Oncol.</i> 2016; <b>17</b>(5): 642–50. <a target=xrefwindow id=d2822e2553 href="http://www.ncbi.nlm.nih.gov/pubmed/27080216">PubMed Abstract </a> | <a target=xrefwindow id=d2822e2557 href="http://dx.doi.org/10.1016/S1470-2045(16)00077-2">Publisher Full Text </a> | <a target=xrefwindow id=d2822e2560 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5006181">Free Full Text </a></span></li><li><a name=ref-65 class=n-a></a><span class=label>65. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/717958121"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2822e2569 class=n-a></a>Flaherty KT, Infante JR, Daud A, <i> et al.</i>: Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. <i>N Engl J Med.</i> 2012; <b>367</b>(18): 1694–703. <a target=xrefwindow id=d2822e2580 href="http://www.ncbi.nlm.nih.gov/pubmed/23020132">PubMed Abstract </a> | <a target=xrefwindow id=d2822e2583 href="http://dx.doi.org/10.1056/NEJMoa1210093">Publisher Full Text </a> | <a target=xrefwindow id=d2822e2587 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3549295">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/717958121">F1000 Recommendation</a></span></li><li><a name=ref-66 class=n-a></a><span class=label>66. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/718892074"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2822e2601 class=n-a></a>Larkin J, Ascierto PA, Dréno B, <i> et al.</i>: Combined vemurafenib and cobimetinib in <i>BRAF</i>-mutated melanoma. <i>N Engl J Med.</i> 2014; <b>371</b>(20): 1867–76. <a target=xrefwindow id=d2822e2615 href="http://www.ncbi.nlm.nih.gov/pubmed/25265494">PubMed Abstract </a> | <a target=xrefwindow id=d2822e2619 href="http://dx.doi.org/10.1056/NEJMoa1408868">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/718892074">F1000 Recommendation</a></span></li><li><a name=ref-67 class=n-a></a><span class=label>67. </span>&nbsp;<span class=citation><a name=d2822e2632 class=n-a></a>Long GV, Flaherty KT, Stroyakovskiy D, <i> et al.</i>: Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic <i>BRAF</i> V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. <i>Ann Oncol.</i> 2017; <b>28</b>(7): 1631–9. <a target=xrefwindow id=d2822e2646 href="http://www.ncbi.nlm.nih.gov/pubmed/28475671">PubMed Abstract </a> | <a target=xrefwindow id=d2822e2650 href="http://dx.doi.org/10.1093/annonc/mdx176">Publisher Full Text </a></span></li><li><a name=ref-68 class=n-a></a><span class=label>68. </span>&nbsp;<span class=citation><a name=d2822e2659 class=n-a></a>Planchard D, Besse B, Groen HJM, <i> et al.</i>: Dabrafenib plus trametinib in patients with previously treated <i>BRAF</i><sup>V600E</sup>-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. <i>Lancet Oncol.</i> 2016; <b>17</b>(7): 984–93. <a target=xrefwindow id=d2822e2675 href="http://www.ncbi.nlm.nih.gov/pubmed/27283860">PubMed Abstract </a> | <a target=xrefwindow id=d2822e2679 href="http://dx.doi.org/10.1016/S1470-2045(16)30146-2">Publisher Full Text </a> | <a target=xrefwindow id=d2822e2682 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4993103">Free Full Text </a></span></li><li><a name=ref-69 class=n-a></a><span class=label>69. </span>&nbsp;<span class=citation><a name=d2822e2691 class=n-a></a>Skobe M, Rockwell P, Goldstein N, <i> et al.</i>: Halting angiogenesis suppresses carcinoma cell invasion. <i>Nat Med.</i> 1997; <b>3</b>(11): 1222–7. <a target=xrefwindow id=d2822e2702 href="http://www.ncbi.nlm.nih.gov/pubmed/9359696">PubMed Abstract </a> | <a target=xrefwindow id=d2822e2705 href="http://dx.doi.org/10.1038/nm1197-1222">Publisher Full Text </a></span></li><li><a name=ref-70 class=n-a></a><span class=label>70. </span>&nbsp;<span class=citation><a name=d2822e2714 class=n-a></a>Sandler A, Gray R, Perry MC, <i> et al.</i>: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. <i>N Engl J Med.</i> 2006; <b>355</b>(24): 2542–50. <a target=xrefwindow id=d2822e2725 href="http://www.ncbi.nlm.nih.gov/pubmed/17167137">PubMed Abstract </a> | <a target=xrefwindow id=d2822e2728 href="http://dx.doi.org/10.1056/NEJMoa061884">Publisher Full Text </a></span></li><li><a name=ref-71 class=n-a></a><span class=label>71. </span>&nbsp;<span class=citation><a name=d2822e2737 class=n-a></a>Spratlin JL, Cohen RB, Eadens M, <i> et al.</i>: Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G<sub>1</sub> monoclonal antibody targeting the vascular endothelial growth factor receptor-2. <i>J Clin Oncol.</i> 2010; <b>28</b>(5): 780–7. <a target=xrefwindow id=d2822e2751 href="http://www.ncbi.nlm.nih.gov/pubmed/20048182">PubMed Abstract </a> | <a target=xrefwindow id=d2822e2755 href="http://dx.doi.org/10.1200/JCO.2009.23.7537">Publisher Full Text </a> | <a target=xrefwindow id=d2822e2758 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2834394">Free Full Text </a></span></li><li><a name=ref-72 class=n-a></a><span class=label>72. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/718451079"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2822e2768 class=n-a></a>Garon EB, Ciuleanu TE, Arrieta O, <i> et al.</i>: Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. <i>Lancet.</i> 2014; <b>384</b>(9944): 665–73. <a target=xrefwindow id=d2822e2779 href="http://www.ncbi.nlm.nih.gov/pubmed/24933332">PubMed Abstract </a> | <a target=xrefwindow id=d2822e2782 href="http://dx.doi.org/10.1016/S0140-6736(14)60845-X">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/718451079">F1000 Recommendation</a></span></li><li><a name=ref-73 class=n-a></a><span class=label>73. </span>&nbsp;<span class=citation><a name=d2822e2795 class=n-a></a>Rudd CE, Taylor A, Schneider H: CD28 and CTLA-4 coreceptor expression and signal transduction. <i>Immunol Rev.</i> 2009; <b>229</b>(1): 12–26. <a target=xrefwindow id=d2822e2803 href="http://www.ncbi.nlm.nih.gov/pubmed/19426212">PubMed Abstract </a> | <a target=xrefwindow id=d2822e2806 href="http://dx.doi.org/10.1111/j.1600-065X.2009.00770.x">Publisher Full Text </a> | <a target=xrefwindow id=d2822e2809 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4186963">Free Full Text </a></span></li><li><a name=ref-74 class=n-a></a><span class=label>74. </span>&nbsp;<span class=citation><a name=d2822e2818 class=n-a></a>Wolchok JD, Saenger Y: The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation. <i>Oncologist.</i> 2008; <b>13 Suppl 4</b>: 2–9. <a target=xrefwindow id=d2822e2826 href="http://www.ncbi.nlm.nih.gov/pubmed/19001145">PubMed Abstract </a> | <a target=xrefwindow id=d2822e2829 href="http://dx.doi.org/10.1634/theoncologist.13-S4-2">Publisher Full Text </a></span></li><li><a name=ref-75 class=n-a></a><span class=label>75. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/4128956"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2822e2838 class=n-a></a>Hodi FS, O’Day SJ, McDermott DF, <i> et al.</i>: Improved survival with ipilimumab in patients with metastatic melanoma. <i>N Engl J Med.</i> 2010; <b>363</b>(8): 711–23. <a target=xrefwindow id=d2822e2849 href="http://www.ncbi.nlm.nih.gov/pubmed/20525992">PubMed Abstract </a> | <a target=xrefwindow id=d2822e2852 href="http://dx.doi.org/10.1056/NEJMoa1003466">Publisher Full Text </a> | <a target=xrefwindow id=d2822e2856 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3549297">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/4128956">F1000 Recommendation</a></span></li><li><a name=ref-76 class=n-a></a><span class=label>76. </span>&nbsp;<span class=citation><a name=d2822e2869 class=n-a></a>Pardoll DM: The blockade of immune checkpoints in cancer immunotherapy. <i>Nat Rev Cancer.</i> 2012; <b>12</b>(4): 252–64. <a target=xrefwindow id=d2822e2877 href="http://www.ncbi.nlm.nih.gov/pubmed/22437870">PubMed Abstract </a> | <a target=xrefwindow id=d2822e2880 href="http://dx.doi.org/10.1038/nrc3239">Publisher Full Text </a> | <a target=xrefwindow id=d2822e2883 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4856023">Free Full Text </a></span></li><li><a name=ref-77 class=n-a></a><span class=label>77. </span>&nbsp;<span class=citation><a name=d2822e2892 class=n-a></a>Scheel AH, Ansén S, Schultheis AM, <i> et al.</i>: PD-L1 expression in non-small cell lung cancer: Correlations with genetic alterations. <i>Oncoimmunology.</i> 2016; <b>5</b>(5): e1131379. <a target=xrefwindow id=d2822e2903 href="http://www.ncbi.nlm.nih.gov/pubmed/27467949">PubMed Abstract </a> | <a target=xrefwindow id=d2822e2906 href="http://dx.doi.org/10.1080/2162402X.2015.1131379">Publisher Full Text </a> | <a target=xrefwindow id=d2822e2910 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4910698">Free Full Text </a></span></li><li><a name=ref-78 class=n-a></a><span class=label>78. </span>&nbsp;<span class=citation><a name=d2822e2920 class=n-a></a>Brahmer J, Reckamp KL, Baas P, <i> et al.</i>: Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. <i>N Engl J Med.</i> 2015; <b>373</b>(2): 123–35. <a target=xrefwindow id=d2822e2931 href="http://www.ncbi.nlm.nih.gov/pubmed/26028407">PubMed Abstract </a> | <a target=xrefwindow id=d2822e2934 href="http://dx.doi.org/10.1056/NEJMoa1504627">Publisher Full Text </a> | <a target=xrefwindow id=d2822e2938 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4681400">Free Full Text </a></span></li><li><a name=ref-79 class=n-a></a><span class=label>79. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725813702"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2822e2947 class=n-a></a>Borghaei H, Paz-Ares L, Horn L, <i> et al.</i>: Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. <i>N Engl J Med.</i> 2015; <b>373</b>(17): 1627–39. <a target=xrefwindow id=d2822e2958 href="http://www.ncbi.nlm.nih.gov/pubmed/26412456">PubMed Abstract </a> | <a target=xrefwindow id=d2822e2961 href="http://dx.doi.org/10.1056/NEJMoa1507643">Publisher Full Text </a> | <a target=xrefwindow id=d2822e2965 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5705936">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725813702">F1000 Recommendation</a></span></li><li><a name=ref-80 class=n-a></a><span class=label>80. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726215272"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2822e2978 class=n-a></a>Fehrenbacher L, Spira A, Ballinger M, <i> et al.</i>: Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. <i>Lancet.</i> 2016; <b>387</b>(10030): 1837–46. <a target=xrefwindow id=d2822e2989 href="http://www.ncbi.nlm.nih.gov/pubmed/26970723">PubMed Abstract </a> | <a target=xrefwindow id=d2822e2992 href="http://dx.doi.org/10.1016/S0140-6736(16)00587-0">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726215272">F1000 Recommendation</a></span></li><li><a name=ref-81 class=n-a></a><span class=label>81. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726044364"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2822e3005 class=n-a></a>Herbst RS, Baas P, Kim DW, <i> et al.</i>: Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. <i>Lancet.</i> 2016; <b>387</b>(10027): 1540–50. <a target=xrefwindow id=d2822e3016 href="http://www.ncbi.nlm.nih.gov/pubmed/26712084">PubMed Abstract </a> | <a target=xrefwindow id=d2822e3019 href="http://dx.doi.org/10.1016/S0140-6736(15)01281-7">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726044364">F1000 Recommendation</a></span></li><li><a name=ref-82 class=n-a></a><span class=label>82. </span>&nbsp;<span class=citation><a name=d2822e3032 class=n-a></a>Chen DS, Irving BA, Hodi FS: Molecular pathways: next-generation immunotherapy--inhibiting programmed death-ligand 1 and programmed death-1. <i>Clin Cancer Res.</i> 2012; <b>18</b>(24): 6580–7. <a target=xrefwindow id=d2822e3040 href="http://www.ncbi.nlm.nih.gov/pubmed/23087408">PubMed Abstract </a> | <a target=xrefwindow id=d2822e3043 href="http://dx.doi.org/10.1158/1078-0432.CCR-12-1362">Publisher Full Text </a></span></li><li><a name=ref-83 class=n-a></a><span class=label>83. </span>&nbsp;<span class=citation><a name=d2822e3052 class=n-a></a>Rizvi NA, Hellmann MD, Brahmer JR, <i> et al.</i>: Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. <i>J Clin Oncol.</i> 2016; <b>34</b>(25): 2969–79. <a target=xrefwindow id=d2822e3063 href="http://www.ncbi.nlm.nih.gov/pubmed/27354481">PubMed Abstract </a> | <a target=xrefwindow id=d2822e3066 href="http://dx.doi.org/10.1200/JCO.2016.66.9861">Publisher Full Text </a> | <a target=xrefwindow id=d2822e3070 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5569693">Free Full Text </a></span></li><li><a name=ref-84 class=n-a></a><span class=label>84. </span>&nbsp;<span class=citation><a name=d2822e3080 class=n-a></a>Landi L, Cappuzzo F: Management of NSCLC: focus on crizotinib. <i>Expert Opin Pharmacother.</i> 2014; <b>15</b>(17): 2587–97. <a target=xrefwindow id=d2822e3088 href="http://www.ncbi.nlm.nih.gov/pubmed/25301075">PubMed Abstract </a> | <a target=xrefwindow id=d2822e3091 href="http://dx.doi.org/10.1517/14656566.2014.970174">Publisher Full Text </a></span></li><li><a name=ref-85 class=n-a></a><span class=label>85. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/727089161"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2822e3100 class=n-a></a>Hellmann MD, Rizvi NA, Goldman JW, <i> et al.</i>: Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. <i>Lancet Oncol.</i> 2017; <b>18</b>(1): 31–41. <a target=xrefwindow id=d2822e3111 href="http://www.ncbi.nlm.nih.gov/pubmed/27932067">PubMed Abstract </a> | <a target=xrefwindow id=d2822e3114 href="http://dx.doi.org/10.1016/S1470-2045(16)30624-6">Publisher Full Text </a> | <a target=xrefwindow id=d2822e3118 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5476941">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/727089161">F1000 Recommendation</a></span></li><li><a name=ref-86 class=n-a></a><span class=label>86. </span>&nbsp;<span class=citation><a name=d2822e3131 class=n-a></a>Hirsh V: Managing treatment-related adverse events associated with egfr tyrosine kinase inhibitors in advanced non-small-cell lung cancer. <i>Curr Oncol.</i> 2011; <b>18</b>(3): 126–38. <a target=xrefwindow id=d2822e3139 href="http://www.ncbi.nlm.nih.gov/pubmed/21655159">PubMed Abstract </a> | <a target=xrefwindow id=d2822e3142 href="http://dx.doi.org/10.3747/co.v18i3.877">Publisher Full Text </a> | <a target=xrefwindow id=d2822e3145 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3108866">Free Full Text </a></span></li><li><a name=ref-87 class=n-a></a><span class=label>87. </span>&nbsp;<span class=citation><a name=d2822e3154 class=n-a></a>O’Sullivan Coyne G, Madan RA, Gulley JL: Nivolumab: promising survival signal coupled with limited toxicity raises expectations. <i>J Clin Oncol.</i> 2014; <b>32</b>(10): 986–8. <a target=xrefwindow id=d2822e3162 href="http://www.ncbi.nlm.nih.gov/pubmed/24590655">PubMed Abstract </a> | <a target=xrefwindow id=d2822e3165 href="http://dx.doi.org/10.1200/JCO.2013.54.5996">Publisher Full Text </a></span></li><li><a name=ref-88 class=n-a></a><span class=label>88. </span>&nbsp;<span class=citation><a name=d2822e3174 class=n-a></a>Gauden S, Ramsay J, Tripcony L: The curative treatment by radiotherapy alone of stage I non-small cell carcinoma of the lung. <i>Chest.</i> 1995; <b>108</b>(5): 1278–82. <a target=xrefwindow id=d2822e3182 href="http://www.ncbi.nlm.nih.gov/pubmed/7587429">PubMed Abstract </a> | <a target=xrefwindow id=d2822e3185 href="http://dx.doi.org/10.1378/chest.108.5.1278">Publisher Full Text </a></span></li><li><a name=ref-89 class=n-a></a><span class=label>89. </span>&nbsp;<span class=citation><a name=d2822e3194 class=n-a></a>Haffty BG, Goldberg NB, Gerstley J, <i> et al.</i>: Results of radical radiation therapy in clinical stage I, technically operable non-small cell lung cancer. <i>Int J Radiat Oncol Biol Phys.</i> 1988; <b>15</b>(1): 69–73. <a target=xrefwindow id=d2822e3205 href="http://www.ncbi.nlm.nih.gov/pubmed/2839443">PubMed Abstract </a> | <a target=xrefwindow id=d2822e3208 href="http://dx.doi.org/10.1016/0360-3016(88)90348-3">Publisher Full Text </a></span></li><li><a name=ref-90 class=n-a></a><span class=label>90. </span>&nbsp;<span class=citation><a name=d2822e3218 class=n-a></a>Senan S: Stereotactic body radiotherapy: do central lung tumors still represent a 'no-fly zone'? <i>Onkologie.</i> 2012; <b>35</b>(7–8): 406–7. <a target=xrefwindow id=d2822e3226 href="http://www.ncbi.nlm.nih.gov/pubmed/22846970">PubMed Abstract </a> | <a target=xrefwindow id=d2822e3229 href="http://dx.doi.org/10.1159/000341091">Publisher Full Text </a></span></li><li><a name=ref-91 class=n-a></a><span class=label>91. </span>&nbsp;<span class=citation><a name=d2822e3238 class=n-a></a>Fang LC, Komaki R, Allen P, <i> et al.</i>: Comparison of outcomes for patients with medically inoperable Stage I non-small-cell lung cancer treated with two-dimensional vs. three-dimensional radiotherapy. <i>Int J Radiat Oncol Biol Phys.</i> 2006; <b>66</b>(1): 108–16. <a target=xrefwindow id=d2822e3249 href="http://www.ncbi.nlm.nih.gov/pubmed/16904517">PubMed Abstract </a> | <a target=xrefwindow id=d2822e3252 href="http://dx.doi.org/10.1016/j.ijrobp.2006.04.015">Publisher Full Text </a></span></li><li><a name=ref-92 class=n-a></a><span class=label>92. </span>&nbsp;<span class=citation><a name=d2822e3261 class=n-a></a>Chang JY, Senan S, Paul MA, <i> et al.</i>: Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. <i>Lancet Oncol.</i> 2015; <b>16</b>(6): 630–7. <a target=xrefwindow id=d2822e3272 href="http://www.ncbi.nlm.nih.gov/pubmed/25981812">PubMed Abstract </a> | <a target=xrefwindow id=d2822e3275 href="http://dx.doi.org/10.1016/S1470-2045(15)70168-3">Publisher Full Text </a> | <a target=xrefwindow id=d2822e3279 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4489408">Free Full Text </a></span></li><li><a name=ref-93 class=n-a></a><span class=label>93. </span>&nbsp;<span class=citation><a name=d2822e3288 class=n-a></a>Su S, Hu Y, Ouyang W, <i> et al.</i>: Might radiation therapy in addition to chemotherapy improve overall survival of patients with non-oligometastatic Stage IV non-small cell lung cancer?: Secondary analysis of two prospective studies. <i>BMC Cancer.</i> 2016; <b>16</b>(1): 908. <a target=xrefwindow id=d2822e3299 href="http://www.ncbi.nlm.nih.gov/pubmed/27871270">PubMed Abstract </a> | <a target=xrefwindow id=d2822e3302 href="http://dx.doi.org/10.1186/s12885-016-2952-3">Publisher Full Text </a> | <a target=xrefwindow id=d2822e3306 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5117544">Free Full Text </a></span></li><li><a name=ref-94 class=n-a></a><span class=label>94. </span>&nbsp;<span class=citation><a name=d2822e3315 class=n-a></a>Yang TJ, Wu AJ: Cranial irradiation in patients with <i>EGFR</i>-mutant non-small cell lung cancer brain metastases. <i>Transl Lung Cancer Res.</i> 2016; <b>5</b>(1): 134–137. <a target=xrefwindow id=d2822e3326 href="http://www.ncbi.nlm.nih.gov/pubmed/26958508">PubMed Abstract </a> | <a target=xrefwindow id=d2822e3329 href="http://dx.doi.org/10.3978/j.issn.2218-6751.2016.01.08">Publisher Full Text </a> | <a target=xrefwindow id=d2822e3333 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4758984">Free Full Text </a></span></li><li><a name=ref-95 class=n-a></a><span class=label>95. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/1016183"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2822e3342 class=n-a></a>Paez JG, Jänne PA, Lee JC, <i> et al.</i>: <i>EGFR</i> mutations in lung cancer: correlation with clinical response to gefitinib therapy. <i>Science.</i> 2004; <b>304</b>(5676): 1497–500. <a target=xrefwindow id=d2822e3356 href="http://www.ncbi.nlm.nih.gov/pubmed/15118125">PubMed Abstract </a> | <a target=xrefwindow id=d2822e3360 href="http://dx.doi.org/10.1126/science.1099314">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/1016183">F1000 Recommendation</a></span></li><li><a name=ref-96 class=n-a></a><span class=label>96. </span>&nbsp;<span class=citation><a name=d2822e3374 class=n-a></a>Hsu PK, Lin WC, Chang YC, <i> et al.</i>: Multiinstitutional analysis of single-port video-assisted thoracoscopic anatomical resection for primary lung cancer. <i>Ann Thorac Surg.</i> 2015; <b>99</b>(5): 1739–44. <a target=xrefwindow id=d2822e3385 href="http://www.ncbi.nlm.nih.gov/pubmed/25827674">PubMed Abstract </a> | <a target=xrefwindow id=d2822e3388 href="http://dx.doi.org/10.1016/j.athoracsur.2015.01.041">Publisher Full Text </a></span></li><li><a name=ref-97 class=n-a></a><span class=label>97. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/718187727"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2822e3397 class=n-a></a>Altorki NK, Yip R, Hanaoka T, <i> et al.</i>: Sublobar resection is equivalent to lobectomy for clinical stage 1A lung cancer in solid nodules. <i>J Thorac Cardiovasc Surg.</i> 2014; <b>147</b>(2): 754–62; Discussion 762–4. <a target=xrefwindow id=d2822e3408 href="http://www.ncbi.nlm.nih.gov/pubmed/24280722">PubMed Abstract </a> | <a target=xrefwindow id=d2822e3411 href="http://dx.doi.org/10.1016/j.jtcvs.2013.09.065">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/718187727">F1000 Recommendation</a></span></li><li><a name=ref-98 class=n-a></a><span class=label>98. </span>&nbsp;<span class=citation><a name=d2822e3424 class=n-a></a>Burdett S, Pignon JP, Tierney J, <i> et al.</i>: Adjuvant chemotherapy for resected early-stage non-small cell lung cancer. <i>Cochrane Database Syst Rev.</i> 2015; (3): CD011430. <a target=xrefwindow id=d2822e3432 href="http://www.ncbi.nlm.nih.gov/pubmed/25730344">PubMed Abstract </a> | <a target=xrefwindow id=d2822e3435 href="http://dx.doi.org/10.1002/14651858.CD011430">Publisher Full Text </a></span></li><li><a name=ref-99 class=n-a></a><span class=label>99. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/717989836"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2822e3444 class=n-a></a>National Lung Screening Trial Research Team, Aberle DR, Adams AM, <i> et al.</i>: Reduced lung-cancer mortality with low-dose computed tomographic screening. <i>N Engl J Med.</i> 2011; <b>365</b>(5): 395–409. <a target=xrefwindow id=d2822e3455 href="http://www.ncbi.nlm.nih.gov/pubmed/21714641">PubMed Abstract </a> | <a target=xrefwindow id=d2822e3458 href="http://dx.doi.org/10.1056/NEJMoa1102873">Publisher Full Text </a> | <a target=xrefwindow id=d2822e3462 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4356534">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/717989836">F1000 Recommendation</a></span></li><li><a name=ref-100 class=n-a></a><span class=label>100. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/717989837"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2822e3475 class=n-a></a>National Lung Screening Trial Research Team, Aberle DR, Berg CD, <i> et al.</i>: The National Lung Screening Trial: overview and study design. <i>Radiology.</i> 2011; <b>258</b>(1): 243–53. <a target=xrefwindow id=d2822e3486 href="http://www.ncbi.nlm.nih.gov/pubmed/21045183">PubMed Abstract </a> | <a target=xrefwindow id=d2822e3489 href="http://dx.doi.org/10.1148/radiol.10091808">Publisher Full Text </a> | <a target=xrefwindow id=d2822e3493 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3009383">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/717989837">F1000 Recommendation</a></span></li><li><a name=ref-101 class=n-a></a><span class=label>101. </span>&nbsp;<span class=citation><a name=d2822e3506 class=n-a></a>Pedersen JH, Rzyman W, Veronesi G, <i> et al.</i>: Recommendations from the European Society of Thoracic Surgeons (ESTS) regarding computed tomography screening for lung cancer in Europe. <i>Eur J Cardiothorac Surg.</i> 2017; <b>51</b>(3): 411–20. <a target=xrefwindow id=d2822e3517 href="http://www.ncbi.nlm.nih.gov/pubmed/28137752">PubMed Abstract </a> | <a target=xrefwindow id=d2822e3520 href="http://dx.doi.org/10.1093/ejcts/ezw418">Publisher Full Text </a></span></li><li><a name=ref-102 class=n-a></a><span class=label>102. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/727261079"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2822e3530 class=n-a></a>Rami-Porta R, Asamura H, Travis WD, <i> et al.</i>: Lung cancer - major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. <i>CA Cancer J Clin.</i> 2017; <b>67</b>(2): 138–55. <a target=xrefwindow id=d2822e3541 href="http://www.ncbi.nlm.nih.gov/pubmed/28140453">PubMed Abstract </a> | <a target=xrefwindow id=d2822e3544 href="http://dx.doi.org/10.3322/caac.21390">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/727261079">F1000 Recommendation</a></span></li><li><a name=ref-103 class=n-a></a><span class=label>103. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725757738"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2822e3557 class=n-a></a>Travis WD, Brambilla E, Nicholson AG, <i> et al.</i>: The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. <i>J Thorac Oncol.</i> 2015; <b>10</b>(9): 1243–60. <a target=xrefwindow id=d2822e3568 href="http://www.ncbi.nlm.nih.gov/pubmed/26291008">PubMed Abstract </a> | <a target=xrefwindow id=d2822e3571 href="http://dx.doi.org/10.1097/JTO.0000000000000630">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725757738">F1000 Recommendation</a></span></li><li><a name=ref-104 class=n-a></a><span class=label>104. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725496365"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d2822e3584 class=n-a></a>McElnay PJ, Choong A, Jordan E, <i> et al.</i>: Outcome of surgery versus radiotherapy after induction treatment in patients with N2 disease: systematic review and meta-analysis of randomised trials. <i>Thorax.</i> 2015; <b>70</b>(8): 764–8. <a target=xrefwindow id=d2822e3595 href="http://www.ncbi.nlm.nih.gov/pubmed/25967753">PubMed Abstract </a> | <a target=xrefwindow id=d2822e3598 href="http://dx.doi.org/10.1136/thoraxjnl-2014-206292">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725496365">F1000 Recommendation</a></span></li><li><a name=ref-105 class=n-a></a><span class=label>105. </span>&nbsp;<span class=citation><a name=d2822e3611 class=n-a></a>Tsao AS, Scagliotti GV, Bunn PA Jr, <i> et al.</i>: Scientific Advances in Lung Cancer 2015. <i>J Thorac Oncol.</i> 2016; <b>11</b>(5): 613–38. <a target=xrefwindow id=d2822e3622 href="http://www.ncbi.nlm.nih.gov/pubmed/27013409">PubMed Abstract </a> | <a target=xrefwindow id=d2822e3625 href="http://dx.doi.org/10.1016/j.jtho.2016.03.012">Publisher Full Text </a></span></li><li><a name=ref-106 class=n-a></a><span class=label>106. </span>&nbsp;<span class=citation><a name=d2822e3634 class=n-a></a>Yamaguchi M, Edagawa M, Suzuki Y, <i> et al.</i>: Pulmonary Resection for Synchronous M1b-cStage IV Non-Small Cell Lung Cancer Patients. <i>Ann Thorac Surg.</i> 2017; <b>103</b>(5): 1594–9. <a target=xrefwindow id=d2822e3645 href="http://www.ncbi.nlm.nih.gov/pubmed/27863731">PubMed Abstract </a> | <a target=xrefwindow id=d2822e3648 href="http://dx.doi.org/10.1016/j.athoracsur.2016.08.098">Publisher Full Text </a></span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 07 Dec 2017</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/6-2110.html&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/6-2110.html&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> Division of Pulmonary and Critical Care Medicine, Virginia Commonwealth University, Richmond, USA<br/> <p> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/6-2110/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 07 Dec 2017, 6:2110 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.11471.1">https://doi.org/10.12688/f1000research.11471.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> © 2017 Shojaee S and Nana-Sinkam P. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=12385 data-id=11471 data-downloads="" data-views="" data-scholar="10.12688/f1000research.11471.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/6-2110/v1/pdf?article_uuid=8e23a256-da3b-465b-8d24-de97c29308d5" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.11471.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Shojaee S and Nana-Sinkam P. Recent advances in the management of non-small cell lung cancer [version 1; peer review: 2 approved] <i>F1000Research</i> 2017, <b>6</b>(F1000 Faculty Rev):2110 (<a href="https://doi.org/10.12688/f1000research.11471.1" target=_blank>https://doi.org/10.12688/f1000research.11471.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=11471 id=mobile-track-article-signin-11471 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/11471?target=/articles/6-2110.html"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=12385 /> <input name=articleId type=hidden value=11471 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>Rita Chiari</strong>, Department of Medical Oncology, Santa Maria della Misericordia Hospital, Azienda Ospedaliera di Perugia, Italy </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Paul Van Schil</strong>, Department of Thoracic and Vascular Surgery, Antwerp University Hospital, Belgium </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> <span class=approved-referee__co-referee> <strong>Patrick Pauwels</strong>, Department of Pathology, Antwerp University Hospital, Belgium </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 07 Dec 2017</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/6-2110.html&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/6-2110.html&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=28504-28461></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=28505-28462></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=2><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/6-2110/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>07 Dec 17</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Rita Chiari</strong>, Department of Medical Oncology, Santa Maria della Misericordia Hospital, Azienda Ospedaliera di Perugia, Italy </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Paul Van Schil</strong>, Department of Thoracic and Vascular Surgery, Antwerp University Hospital, Belgium </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> <p class=" u-mt--2 u-mb--1/2"><strong>Patrick Pauwels</strong>, Department of Pathology, Antwerp University Hospital, Belgium </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/6-2110.html&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/6-2110/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "Recent advances in the management of non-small...".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/6-2110/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/6-2110/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/6-2110/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Shojaee S and Nana-Sinkam P');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/6-2110/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/6-2110",
            templates : {
                twitter : "Recent advances in the management of non-small cell lung cancer. Shojaee S and Nana-Sinkam P, published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/6-2110/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: Recent advances in the management of non-small cell lung cancer", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: Recent advances in the management of non-small cell lung cancer", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/11471/12385")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "12385");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "28461": 0,
                           "28462": 0,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "32266938-c7d7-40f2-9dbc-dc31f694e799";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/6-2110.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/6-2110.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/6-2110.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/6-2110.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/6-2110.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>